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Abstract
The 2014-2016 West Africa epidemic was the worst Ebola virus outbreak on record, with the infected
numbering over 28,000 and the dead more than 11,000. Among those who survived the disease, Ebola virus
was found to persist in numerous anatomical locations and be shed in semen. During the West Africa
outbreak, numerous occurrences of Ebola sexual transmission were documented. While sexual transmission
has the potential to compromise public health eradication efforts and reignite outbreaks, no molecular details
of host factors influencing this phenomenon are known. Amyloid fibrils present in healthy individuals’ semen
have been suggested to be a host factor that aids in sexual transmission of viruses including HIV-1. To
understand if seminal amyloid fibrils increase infection by Ebola virus, a recombinant virus expressing the
Ebola glycoprotein was preincubated with the type species of the seminal amyloids, SEVI. When present,
SEVI resulted in a nearly 20-fold increase in infection of physiologically relevant target cells. SEVI and other
seminal amyloids were also found to enhance authentic Ebola virus infection by 20- to 40-fold in cell culture.
Mechanistically, SEVI was found to increase viral attachment then subsequent internalization of virus through
macropinocytosis, a previously unknown ability to enhance uptake by this mechanism critical for Ebola virus
entry. Finally, a new ability of SEVI to enhance viral stability during incubation at physiologic temperatures
and under desiccating conditions is described, a finding important for transmission biology. Together, these
functions of seminal amyloids represent a first step toward understanding Ebola virus sexual transmission at a
molecular level and provide potential therapeutic targets to prevent transmission by this route.
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ABSTRACT 
 
ENHANCEMENT OF EBOLA VIRUS INFECTION BY SEMINAL AMYLOID FIBRILS 
Stephen Michael Bart 
Paul Bates 
 
The 2014-2016 West Africa epidemic was the worst Ebola virus outbreak on record, with the 
infected numbering over 28,000 and the dead more than 11,000. Among those who survived the 
disease, Ebola virus was found to persist in numerous anatomical locations and be shed in semen. 
During the West Africa outbreak, numerous occurrences of Ebola sexual transmission were 
documented. While sexual transmission has the potential to compromise public health eradication 
efforts and reignite outbreaks, no molecular details of host factors influencing this phenomenon are 
known. Amyloid fibrils present in healthy individuals’ semen have been suggested to be a host 
factor that aids in sexual transmission of viruses including HIV-1. To understand if seminal amyloid 
fibrils increase infection by Ebola virus, a recombinant virus expressing the Ebola glycoprotein was 
preincubated with the type species of the seminal amyloids, SEVI. When present, SEVI resulted in 
a nearly 20-fold increase in infection of physiologically relevant target cells. SEVI and other seminal 
amyloids were also found to enhance authentic Ebola virus infection by 20- to 40-fold in cell culture. 
Mechanistically, SEVI was found to increase viral attachment then subsequent internalization of 
virus through macropinocytosis, a previously unknown ability to enhance uptake by this mechanism 
critical for Ebola virus entry. Finally, a new ability of SEVI to enhance viral stability during incubation 
at physiologic temperatures and under desiccating conditions is described, a finding important for 
transmission biology. Together, these functions of seminal amyloids represent a first step toward 
understanding Ebola virus sexual transmission at a molecular level and provide potential 
therapeutic targets to prevent transmission by this route. 
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CHAPTER 1 – EBOLA VIRUS 
Ebola virus was first identified in 1976 in the Central African country of Zaire (now 
Democratic Republic of the Congo). Named for the nearby Ebola River, the previously unknown 
virus caused a devastating hemorrhagic disease in the area of the village of Yambuku, killing almost 
90% of those infected. Over the next four decades, the five Ebolavirus species caused sporadic 
and localized outbreaks before the 2014-2016 West African outbreak that infected tens of 
thousands.  
Section 1.1 – Ebola virus epidemiology 
Ebolaviruses, which are Biosafety Level 4 pathogens due to their high pathogenicity, have 
collectively caused 29 documented outbreaks in humans worldwide (Figure 1.11–3). Four of the five 
viral species in the Ebolavirus genus cause Ebola virus disease (EVD) in humans4. Ebola Zaire 
(EBOV) has caused most identified outbreaks, including both the initial 1976 outbreak and the 
2014-2016 West African epidemic, and is the most lethal. Ebola Sudan (SUDV) has also caused 
considerable morbidity and mortality, while Ebola Bundibugyo (BDBV) and Ebola Tai Forest (TAFV) 
have caused smaller, limited outbreaks. The fifth Ebolavirus, Ebola Reston (RESTV), was identified 
in monkeys exported into the United States from the Philippines and causes asymptomatic human 
infections that have been identified only by serology5. The Ebolavirus genus, along with its sister 
genera Marburgvirus (which contains the eponymous Marburg virus, MARV) and Cuevavirus 
(which contains a single species identified only by sequencing of European bats and never 
isolated6), comprise the Filoviridae family. Discounting RESTV, Ebolavirus outbreaks have 
originated exclusively in sub-Saharan Africa, though spread to Europe and North America has 
occurred. Case-fatality ratios for the various outbreaks involving human-to-human transmission 
have ranged from 36-90%2. Most outbreaks have been relatively small and contained to remote 
areas, with the West Africa EBOV outbreak being the exception. 
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 The 2014-2016 West African outbreak is by far the deadliest Ebola outbreak on record. 
The official totals for the outbreak, which are almost certainly underestimates of the true disease 
burden, tally 28,652 cases and 11,325 deaths, a case-fatality ratio (CFR) of 39.5%2. The index 
case of the outbreak is believed to be a 2-year-old child who died in December 2013 in Meliandou, 
Guinea7. This region of Guinea has been heavily deforested and mined, and it is hypothesized that 
habitat destruction may have exposed the EBOV reservoir to the human population8. The virus 
spread to the boy’s family and to others from surrounding villages before reaching the neighboring 
countries of Liberia and Sierra Leone by March 20149. Over the next few months, the virus began 
spreading through major population centers, including the capital cities of Monrovia, Liberia; 
Conakry, Guinea; and Freetown, Sierra Leone. Poor sanitation within urban slums contributed 
greatly to the spread of the virus10. West Africa has not historically been a site of widespread Ebola 
outbreaks in the past, and the most heavily affected countries were ill equipped to respond to the 
outbreak.  
Figure 1.1. Ebola virus outbreaks, 1976-present.  
Ebola virus disease outbreaks (excluding accidental laboratory exposures) are indicated by 
colored circles at the site of the index case, with larger circles indicating more cases. Countries 
reporting at least one human Ebola virus case are colored in dark gray. 
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 The virus spread to several nearby countries, including Senegal, Nigeria, and Mali, as well 
as outside Africa, with cases being diagnosed in Spain, Italy, the United Kingdom, and the United 
States11. These countries exhibited very limited viral spread relative to the most heavily affected 
countries of Guinea, Liberia, and Sierra Leone (Figure 1.2).  
 The particular strain of EBOV causing the outbreak was named the Makona strain and was 
found to be 97% similar to EBOV isolates from the Democratic Republic of the Congo (DRC) and 
Gabon7,12. The strain clusters phylogenetically with the other Zaire ebolavirus species, with about 
400 nucleotide differences across the 19 kb genome separating it and the 1976 EBOV-Mayinga 
strain7. Genomic sequencing confirmed that the outbreak was monophyletic and appeared to 
initiate from a single introduction of the virus into the human population followed by sustained 
human-to-human transmission9.  
 EBOV is transmissible from the beginning of the symptomatic phase, and the infected can 
transmit virus even after death. EBOV is highly infectious; as few as 1-10 aerosolized particles are 
Figure 1.2. Affected countries, 2014-2016 Ebola outbreak. 
Map showing the countries reporting cases of Ebola virus disease during the outbreak initiating 
in West Africa. Darker shades of blue indicate higher numbers of confirmed EVD cases. 
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lethal in non-human primate models of EBOV infection13. The main route of transmission is through 
contact with infected bodily fluids. Those caring for infected relatives and those involved in 
preparation of bodies for burial are at particular risk for EBOV transmission; the latter was 
particularly important during the West African outbreak14. This method of exposure is thought to 
have played a major role in the spread of the virus before public health measures alleviated this 
transmission route. 
The reservoir for Ebolaviruses between outbreaks has yet to be definitively identified, 
though evidence suggests that fruit bats are the most likely culprit. EBOV RNA and antibodies have 
been detected among African bat populations, and seroprevalence of EBOV antibodies increases 
in bat populations during human outbreaks15-17. Further, MARV, a related filovirus, has been 
isolated from African bat species18. Notably, the index case of the West Africa outbreak was 
reported to have been playing in a hollow tree that harbored a large bat population before his 
symptoms began19. Bats do not show symptoms of disease despite high levels of EBOV in the 
blood20. Virus has been found in various wild animal carcasses, including gorillas, chimpanzees, 
and duikers, indicating that infection is not limited to humans21. EBOV outbreaks among 
chimpanzees and gorillas have led to large declines in their populations22,23. Swine have been 
documented as hosts for RESTV in addition to monkeys as previously described24. The role of 
domestic animals as vectors of EBOV transmission is unclear. During a 2002 outbreak of EBOV in 
Gabon, 30% of dogs were seropositive for EBOV, though the specificity of the assay used is 
questionable25. No disease was documented in these animals, and in vitro experiments suggest 
that canine cells are less susceptible to EBOV infection than primate cells (Box 1)26, leaving the 
role of domestic animals in EBOV transmission an open question. 
While EBOV has clearly evolved on a genetic level between the 1976 outbreak and the 
present, there have been no notable changes in viral characteristics over time27. However, due to 
the high degree of person-to-person transmission in the 2014-2016 outbreak, it was hypothesized 
that mutations may have arisen in the virus as it adapted to humans rather than its natural host. 
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One such mutation, at position 82 in the EBOV glycoprotein, arose during the outbreak and was 
subsequently found to increase infectivity of the virus in culture28–30. The increase in infectivity, 
however, comes at a cost to the virus, resulting in decreased glycoprotein stability under 
physiological temperatures30. Bats have a higher physiological temperature than humans (due to 
the higher metabolic rate necessary for flight), potentially explaining why the mutation has not been 
previously seen in outbreaks with less-extensive human-to-human EBOV transmission. 
Section 1.2 – Ebola virus biology 
The EBOV virion is a long, filamentous, enveloped particle of variable length (600 to 1400 
nm) and a uniform diameter (80 nm)31. The EBOV genome comprises a single strand of negative-
sense RNA divided into 7 genes encoding 9 proteins31 (Figure 1.3). The genome is packaged within 
a ribonucleoprotein (RNP) structure composed of nucleoprotein (NP), minor nucleoprotein (VP30), 
and the polymerase complex (L/VP35). The RNP is enclosed within a matrix composed of the 
matrix protein VP40 and the minor matrix protein VP24. The glycoprotein (GP1/GP2, or EboGP) is 
the only virion surface protein and effects attachment to target cells and fusion of the virion and 
cellular membranes. EboGP is thus the target of the neutralizing antibody response in infected 
individuals. Additionally, cells infected with EBOV produce two other nonstructural products from 
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the glycoprotein gene, the secreted glycoprotein (sGP) and small secreted glycoprotein (ssGP). 
These products share a portion of sequence with EboGP; mRNA production for each is a result of 
mRNA editing by polymerase slippage or stuttering, with sGP being the main gene product32,33. 
The function of these soluble glycoproteins is unclear, but they may assist in evading the host 
antibody response34,35. EboGP and VP40 together are sufficient to produce filamentous virus-like 
particles (VLPs) which can mimic the entry process for authentic EBOV36–38. 
EBOV undergoes a unique and complex entry process to infect cells39 (Figure 1.4). The 
first step of viral entry is attachment to the surface of cells by generally nonspecific mechanisms 
with cellular attachment factors40. Characterized interactions include binding of carbohydrates on 
EboGP to C-type lectins such as DC-SIGN and DC-SIGNR41 and direct or indirect binding of 
phosphatidylserine (PS) in the virion membrane with cellular receptors. These cellular PS receptors 
include members of the Tyro3 family of receptor tyrosine kinases (e.g. Axl) and the T cell 
immunoglobin and mucin domain family (e.g. TIM-1)42–46. These attachment factors are abundant 
on dendritic cells (DCs) and macrophages, which represent important early cell types for EBOV 
infection. Interestingly, it is hypothesized that the PS-mediated attachment process reflects 
Figure 1.3. Schematic of EBOV genome organization and virion structure.  
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“apoptotic mimicry,” as apoptotic blebs also present PS on their outer lipid leaflet and are cleared 
by antigen-presenting cells such as DCs and macrophages47. Intact cells employ flippases to 
maintain PS on only the inner leaflet of the plasma membrane and avoid recognition through this 
mechanism.  
Attachment to the surface of the cell triggers the virion internalization by macropinocytosis, 
a relatively nonspecific uptake mechanism involving actin dynamics and membrane ruffling38,48,49. 
Within the cellular endosomal network, the virion requires the activity of the Rab GTPases Rab5 
and Rab7 to traffic to a low pH compartment49. There, cellular cathepsin B/L proteases process 
EboGP, removing part of the glycoprotein and exposing a receptor-binding domain to permit the 
glycoprotein to interact with the cellular cholesterol transporter Niemann-Pick C1 (NPC1) within the 
late endosome50–54. This binding event is necessary to trigger a conformational change within the 
glycoprotein, which results in the fusion of virion and cellular membranes and the release of the 
RNP into the cytoplasm. Within the cytoplasm, the polymerase transcribes and replicates the 
genome, leading to production of new EBOV particles budding from the plasma membrane. 
Figure 1.4. Schematic of EBOV entry into cells. 
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Section 1.3 – Ebola virus disease 
 When EBOV was first described in 1976, the disease it caused was termed Ebola 
hemorrhagic fever (EHF) due to the severe bleeding seen in some patients. Because only a fraction 
of individuals exhibit hemorrhagic symptoms, EHF has been rechristened Ebola virus disease 
(EVD). The incubation period lasts 2-21 days4. Individuals can transmit the virus as soon as they 
are symptomatic, and the first phase of disease is marked by non-specific symptoms typical of viral 
infections (chills, fever, myalgia, etc)4,55. The second phase encompasses additional symptoms 
including lethargy, nausea, vomiting, abdominal pain, anorexia, diarrhea, coughing, headache, and 
hypotension4,55. Hemorrhage is observed in a minority of cases4,55. In severe cases, multi-organ 
failure affecting the cardiovascular, respiratory, and renal systems; hepatic injury; and hypotensive 
shock can contribute to death 6-16 days after onset of symptoms4,55. Viral RNA and antigen can be 
detected in the blood during the symptomatic phase of disease, and antibodies against the virus 
can be detected by serology during and after symptomatic disease56,57. 
In non-human primate models, the first cells in which EBOV antigen can be detected are 
DCs and other cells of the monocyte/macrophage lineage58. In a guinea pig model of infection, 
macrophages positive for the EBOV genome can be detected by in situ hybridization (ISH) 
throughout the disease course in multiple anatomical sites59. Trafficking of these cells to lymph 
nodes and through blood is hypothesized to be a mechanism for spread of EBOV throughout the 
body to other target cells and organs60. Understanding of human pathology is limited by the paucity 
of autopsies due to biosafety concerns61. Hepatocytes are a major target cell for EBOV infection, 
and hepatic necrosis is observed in fatal EBOV cases61. Other cell types found infected by EBOV 
in humans include epidermal DCs, endothelial cells, and connective tissue fibroblasts in the skin61. 
The only cells characterized as resistant to EBOV infection are lymphocytes, though they are 
severely depleted during infection in a mechanism potentially involving TLR462–65. Severe cases of 
disease are marked by massive releases of pro-inflammatory cytokines and vasodilators, which 
likely contributes to pathology66. Recent retrospective analysis of existing guinea pig model tissues 
indicates that numerous cell types are infected that have not been previously appreciated, including 
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(among others) the endocardium, Schwann cells of the peripheral nervous system, smooth muscle 
of the vaginal wall, and the epithelium of the vagina and penis67. Infection at these previously 
overlooked sites may play critical roles in persistent infection (Section 1.4) and sexual transmission 
(Section 1.5). 
Some proportion of individuals exposed to EBOV develop an antibody response while 
experiencing no or only mild symptoms. While determination of this fraction is complicated by 
disparate serological profiles among African populations, recent estimates suggest that a small 
percentage (2-11%) of those serologically positive for EBOV did not show symptoms of disease68,69. 
Individuals are apparently able to transmit virus to others even in the absence of any symptoms70. 
Section 1.4 – Post-Ebola syndrome and persistence 
 A constellation of symptoms, referred to as post-Ebola syndrome, has been described 
among EVD survivors. These symptoms are variable and include headache, ocular pain and vision 
loss, impotence, hearing loss, arthralgia, myalgia, extreme fatigue, anorexia, and neurological 
complications. Among a small cohort of survivors, all reported at least one post-Ebola symptom, 
with headache being most common and reported by a majority of subjects71. As early as 1977, 
when a researcher accidentally infected himself with SUDV and fell ill with EVD, it was known that 
Ebolaviruses could persist even after recovery from disease72. Even in the absence of symptoms 
Figure 1.5. Summary of evidence of filovirus persistence in semen. 
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and after EBOV has been cleared from blood, EBOV can persist in immune privileged sites 
including the central nervous system, eye, mammary glands, and the reproductive system. EBOV 
RNA has been detected in semen 2.5 years after disease (Figure 1.5)73, and persistence in vaginal 
fluids has been documented 33 days post-symptom onset74.  
The issue of persistence came to the forefront during the 2014-2016 West Africa epidemic, 
during which it was appreciated that persistent virus could cause significant issues including uveitis, 
meningoencephalitis, and sexual transmission. Ocular problems, including uveitis, blindness, 
cataracts, and retinal scarring, can be debilitating and correlate with inflammation from persistent 
infection75. One man exhibited a change in eye color associated with persistent EBOV in his eye 
months after his recovery from acute disease76. A woman in the UK suffered from 
meningoencephalitis due to a resurgence of EBOV that was genetically identical to the virus she 
had survived months before, even though she had developed EBOV antibodies77. Perhaps most 
worrying, however, is the potential for transmission of persistent virus to reignite an outbreak in the 
absence of surveillance mechanisms. A case of suspected transmission from mother to child by 
breastfeeding was reported involving a mother who had not shown symptoms of EVD but harbored 
EBOV RNA in her breastmilk70. Further, studies prior to, during, and after the 2014 outbreak have 
demonstrated that filoviruses could persist and be shed in semen for weeks to months following 
infection. For the first time, several cases of EBOV sexual transmission were reported during the 
2014 outbreak, and cohort studies assessed the length of time that EBOV could be detected in 
semen (Figure 1.572–74,78–93). EBOV RNA has been detected in semen up to 965 days following 
infection, though the presence of EBOV RNA does not necessarily imply the presence of infectious 
virus74. Cultivation of EBOV from semen is complicated by semen’s cytotoxic character and 
contamination with bacteria and fungi90,94, but infectious virus has been identified from semen 
collected up to 233 days following EVD by injection into SCID mice90.  
The cell types that sustain persistent EBOV infection have not been well defined in 
humans. Persistent infection likely occurs in tissues that were infected during acute disease but 
failed to clear the virus. Relevant to persistence and shedding of EBOV in semen, EBOV antigen 
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has been detected in the seminiferous tubules, testicular endothelium, and blood vessels of the 
male reproductive system in an EBOV case61. Infection of monkeys shows replication within the 
interstitial cells of the testis95. Monkeys that survived EBOV infection either naturally, after 
vaccination, or after treatment with investigational antivirals showed evidence of viral persistence96. 
Mirroring reports of disease in humans, EBOV RNA and antigen was observed in these archived 
rhesus macaque brain, eye, and epididymis samples weeks after infection96. Immunofluorescence 
microscopy indicated that tissues infected with persistent EBOV had high levels of infiltration by 
CD68+ cells, which are cells of the monocyte/macrophage lineage and known targets for EBOV 
infection96. Both EBOV genome and antigenome were detected by fluorescence in situ 
hybridization in a macaque epididymis sample and EboGP was detected both inside and outside 
of cells by immunofluorescence96. These data suggest ongoing replication and perhaps virion 
production at the time of death. 
Section 1.5 – Ebola sexual transmission 
In 1968, a doctor returned to Marburg, Germany after contracting an unknown hemorrhagic 
disease in Africa. Two months after he recovered, he transmitted the virus, then christened MARV, 
to his wife by sexual transmission and initiated a small outbreak93. His semen was found to be 
infectious in a guinea pig model93. Sexual transmission of EBOV had never been rigorously 
demonstrated before the 2014 Ebola outbreak, when several substantiated incidents of male-to-
female EBOV sexual transmission of this persistent virus were reported. The first documented 
occurrence was in Liberia in 2015 when a man who survived EVD sexually transmitted EBOV to 
his wife 180 days following his illness79. While no infectious virus was isolated from his semen, 
EBOV RNA was detected79. The wife’s virus was found to be highly similar to the husband’s virus, 
and phylogenetic analysis showed that the wife’s virus clustered not with the currently circulating 
EBOV isolates but instead with sequences from the village when the husband was ill79. EBOV 
sexual transmission seems to be an uncommon event, as another woman with whom the husband 
had sexual relations apparently did not contract the virus79. The finding that EBOV could be sexually 
transmitted for months after recovery from the virus led the WHO to extend their guidance to EVD 
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survivors to use safer sex practices for one year after their disease. Genomic sequencing data 
have been used to identify transmission chains with evolution rates that are much lower than would 
be expected, a marker for transmission of persistent EBOV. This strategy has been used to identify 
previously overlooked clusters of EBOV sexual transmission97.  
While most sexual transmission events have not been extensively documented and remain 
relatively uncommon, published cases demonstrate potential major public health concerns. A 
modeling study predicted that a three-month infectious period could extend the outbreak by 83 
days, though many of the model criteria were estimated in the absence of reliable data98. 
Importantly, once the virus has been transmitted from a persistently infected source, it can be 
spread through normal mechanisms of contact with bodily fluids. This raises the specter of sexual 
transmission reigniting an outbreak in an area declared free of EBOV transmission, a scenario that 
occurred in Guinea in early 2016. In December 2015, Guinea was declared Ebola-free, but several 
months later in March 2016, a cluster of seven cases was identified that further spread into 
Liberia81. Independent genomic sequencing and epidemiological investigations converged on the 
conclusion that the outbreak was due to sexual transmission of persistent EBOV in a man who had 
EVD 470 days prior81. Notably, this man had observed the WHO guidelines and abstained from 
unprotected sexual contact for one year after his disease, suggesting that the guidelines were 
insufficient to prevent reignition of EBOV transmission chains. The guidelines also suggest that 
male survivors should have their semen tested for the presence of EBOV until negative, and 
screening programs have been set up to provide counseling and monitor seminal persistence 
among survivors99. 
Section 1.6 – Ebola virus disease treatment and prevention 
Treatment for EVD is primarily supportive in nature and no approved therapies exist. Trials 
for some specific therapeutics were conducted during the West Africa outbreak, though issues of 
sample size arose as the outbreak waned in addition to ethical concerns100,101. The standard of 
care for EVD, hydration and electrolyte replacement therapies, counteracts the effects of vascular 
leak and diarrhea102. Because survivors of EVD develop neutralizing antibodies against EboGP, 
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plasma from surviving individuals (convalescent plasma) has been considered as an experimental 
treatment since the 1970s72. In an uncontrolled case series of 8 patients treated with convalescent 
plasma in a 1995 EBOV outbreak in the DRC, 7 survived; the CFR of 12.5% among treated patients 
was much lower than the overall outbreak CFR of 80%103. However, a recent trial of 99 patients 
showed no statistically significant difference in risk of death among EVD patients treated with 
convalescent plasma compared to controls, though there may have been a benefit among pediatric 
patients104. Notably, the plasma used for this trial was not tested for neutralizing capacity before 
infusion. Cocktails of monoclonal antibodies against EboGP have yielded promising results in 
preclinical trials in non-human primates and were used both under compassionate use settings and 
in trials during the outbreak. ZMapp, a cocktail of three human-mouse chimeric monoclonal 
antibodies, was administered to several patients outside of Africa; a majority survived101. A clinical 
trial demonstrated that treatment with ZMapp resulted in a 40% decrease in relative mortality 
among EVD patients, though this difference did not reach predetermined benchmarks to consider 
the treatment superior to standard of care105. A cocktail of three mouse monoclonal antibodies, 
ZMAb, has been used in Europe to treat two patients, both of whom survived101. No further data is 
available on its efficacy in humans. 
Numerous small molecule treatments have been developed to inhibit EBOV replication, but 
few have been tested in humans. Favipiravir, which is licensed in Japan to treat influenza, has been 
described to also have activity against other negative-strand viruses by targeting the viral RNA-
dependent RNA polymerase106. Most EBOV patients treated in Europe received favipiravir. A non-
randomized, historically controlled trial suggested that favipiravir may be efficacious in patients with 
high viral titers107. A clinical trial is ongoing to observe the effects of favipiravir in men whose semen 
remains positive for EBOV after recovery108. Another therapy, TKM-Ebola, is composed of multiple 
short interfering RNA molecules (siRNAs) targeting the EBOV genome. While phase I trials were 
halted due to cytokine abnormalities among participants, two patients in the US received the drug 
along with convalescent plasma and both recovered109. The efficacy of the treatment, however, is 
unknown. The last treatment used in humans during the 2014 outbreak is brincidofovir, a drug that 
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targets DNA virus DNA polymerases and shows activity against EBOV in vitro through an unclear 
mechanism110. Brincidofovir was used to treat one patient in the US and entered phase II trials 
during the outbreak, but the trials were halted due to declining case numbers101,111. 
Finally, several vaccine candidates have arisen over the past few decades. The most 
advanced use viral vectors engineered to express EboGP. A phase III trial of a vaccine composed 
of vesicular stomatitis virus with its own glycoprotein replaced with EboGP showed 100% efficacy 
(95% CI 74.7-100%) when contacts of infected individuals were vaccinated immediately after 
identification in a ring vaccination strategy112. However, numerous adverse events have been 
identified among those vaccinated113. Another vector vaccine, which uses a chimpanzee 
adenovirus to express EboGP followed by a boost with modified vaccinia Ankara expressing 
EboGP, has not completed phase III trials but effectively produces both humoral and cellular 
responses in study participants114. 
Given the high morbidity and mortality associated with EVD, the continued development of 
antiviral agents – both therapeutic and prophylactic – is of high priority. 
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CHAPTER 2: SEMINAL AMYLOID FIBRILS 
Amyloid fibrils are traditionally considered pathologic in nature, being associated with 
degenerative diseases including Alzheimer’s disease, prion diseases, and amyloidosis. In these 
cases, proteins adopt a fold that renders them remarkably stable and insoluble, leading to toxic 
protein aggregation. It has recently been discovered that amyloid fibrils are present in healthy 
individuals and may play an important physiological role. However, like many existing host factors, 
viruses may hijack them to facilitate their own transmission and replication. 
Section 2.1 – Introduction to seminal amyloids 
 The role of semen in sexual transmission of viruses has long been unclear. Semen had 
traditionally been thought to act only as a passive vehicle for the virus, but studies have suggested 
that it may play direct roles in enhancing human immunodeficiency virus type 1 (HIV-1) infection 
by pH neutralization1,2, opsonization3, and recruitment of target cells to the female genital tract4,5. 
To identify additional pro-viral mechanisms, a library of peptides and small proteins derived from 
human semen was screened for factors that modulate HIV-1 infection6. This screen led to the 
identification of fractions that increased HIV-1 infection, and mass spectrometry identified those 
fractions as containing a peptide derived from prostatic acid phosphatase (PAP)6. PAP is a major 
proteinaceous component of semen and is present at 1-2 mg/mL; a 39-amino acid peptide, 
PAP248-286, was recovered at a concentration of 35 μg/mL in semen6. Unexpectedly, when this 
peptide was chemically synthesized, it had no effect on viral infection. It was not until the solutions 
became turbid after short-term agitation or incubation that a pronounced enhancement in viral 
infectivity was noted6. Interestingly, when the turbid solution was analyzed, it was found that the 
PAP248-286 peptides had oligomerized into amyloid fibrils that were termed semen-derived 
enhancer of viral infection (SEVI)6. Amyloid formation was confirmed by electron microscopy and 
increases in fluorescence upon incubation with the amyloid-binding dyes thioflavin T and Congo 
red6. 
 SEVI was found to dramatically enhance the ability of HIV-1 to infect reporter cell lines and 
primary cells6. The enhancement effect was found to be greater at low virus concentrations, a 
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conclusion supported by viral titration experiments indicating a 105-fold enhancement in viral titer6. 
Because HIV-1 infectivity is limited by poor attachment to host cells, likely contributing to the finding 
that less than 0.1% of viral particles are infectious in vitro7,8, this level of enhancement may be very 
significant in terms of disease transmission. The presence of SEVI fibrils was found to reduce the 
number of virions required to establish a productive infection in cell culture by several orders of 
magnitude, from 103-105 down to 1-3 virions6. 
 Subsequent studies have found that SEVI is not the only amyloid present naturally within 
semen. Another fragment of PAP, PAP85-120, is present at a similar concentration in semen and 
was also found to enhance infection by HIV-19. Amyloidogenic fragments of the seminal proteins 
semenogelin-1 and -2 (SEM1 and SEM2)10, which are important components of the seminal 
coagulum, have also been found to enhance HIV-1 infection in vitro. The semenogelin proteins are 
cleaved by prostate specific antigen (PSA)10; the protease responsible for liberation of PAP85-120 
and PAP248-286 fragments is unknown but may originate in the seminal vesicles10.  
Section 2.2 – Mechanism of enhancement by seminal amyloids 
 All seminal amyloids described to date are highly basic. The PAP248-286 peptide which 
forms SEVI has a theoretical isoelectric point of 10.21 owing to its high proportion of positively 
charged residues (8 of 39 are lysine or arginine)6. This positive charge is essential for viral 
enhancement. Replacement of all positive residues on PAP248-286 with alanine does not impact 
its ability to form fibrils but abrogates its ability to enhance HIV-1 infection11. Further, treatment of 
the fibrils with anionic polymers such as dextran sulfate or molecular tweezers that mask the 
positively charged residues abrogates enhancement ability11,12. Combining these results with the 
observations that freshly dissolved peptide does not enhance viral infection, both positive charge 
and amyloid character are necessary for enhancement but neither is sufficient alone. 
 Live-imaging microscopy has revealed that SEVI fibrils are captured by cellular protrusions 
at the plasma membrane6. It is hypothesized that the positively charged PAP248-286 fibrils are 
liberated from PAP by proteolytic cleavage and assemble into SEVI fibrils (Figure 2.1). These fibrils 
bind virion membranes through interactions with negative charges on the virion membrane. The 
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SEVI fibrils then interact with target cells in a similar way, bringing the virion into close proximity 
with the cell membrane. In this way, attachment to the cell is enhanced, leading to increases in 
downstream entry processes including viral fusion6. The interaction between the seminal amyloids 
and virion membranes appears to be glycoprotein-independent to some degree. Similar fold-
increases in cellular attachment have been observed with VLPs formed by the HIV-1 glycoprotein 
and matrix protein p24 and particles formed with p24 alone without a glycoprotein6. Seminal 
amyloids have been further characterized to enhance infection by HIV-1, HIV-2, simian 
immunodeficiency virus (SIV), cytomegalovirus (CMV), herpes simplex virus (HSV), and 
pseudoviruses bearing various glycoproteins on an HIV-1 core13–17. Enhancement may occur 
similarly for all enveloped viruses with similar membrane composition. Electron micrographs 
demonstrate internalization of SEVI fibrils into the cell in the absence of virus, suggesting that the 
fibrils may induce their own internalization6. However, inhibitors of phagocytosis were not sufficient 
to block the enhancement effect observed for HIV-1, which may fuse at the cell surface6. 
Figure 2.1. Model of enhancement of HIV-1 infection by SEVI. 6. 
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Section 2.3 – Seminal amyloids and function 
 The physiological role of seminal amyloids has not been conclusively demonstrated. Sperm 
cells fluoresce when stained with Congo red, an amyloid-specific dye, suggesting that they may be 
coated in seminal amyloids18. SEM-1 and SEM-2 have been observed to bind to spermatozoa by 
immunofluorescence, though it is unclear whether the fraction of these proteins binding is formed 
into amyloid fibrils19. These proteins are under strong positive selection, suggesting these proteins 
may have an important role in evolutionary fitness20,21. Indeed, given the ability of these fibrils to 
enhance viral infection, one may posit that they may be evolutionarily selected against unless 
serving another function. Indeed, phylogenetic analysis suggests that these fibrils are conserved 
among primates, and the analogous peptide to SEVI in macaques enhances viral infection22,23. It 
has been hypothesized that seminal amyloids enhance fertilization through a similar mechanism 
by which they enhance viral infection. In analogous cases, a much smaller membrane-bound 
particle (sperm cell or enveloped virus) must overcome charge repulsion between its membrane 
and its target (egg cell or susceptible host cell). Both scenarios are often dependent upon lipid rafts 
and involve the action of glycoproteins to fuse membranes24. Interestingly, many compounds 
developed to inhibit fertilization will also inhibit viral infection to some degree, and vice versa24. 
 Recent experiments, however, have demonstrated that seminal amyloids (SEVI and 
SEM1) actually inhibit fertilization of mouse gametes25. Subsequently, it was found that binding of 
amyloid fibrils restricted movement by spermatozoa25. In addition, treatment of spermatozoa with 
seminal amyloid fibrils was found to increase their internalization by macrophages, especially if the 
spermatozoa had been damaged by freeze-thaw cycles25. This led to a revised hypothesis that 
seminal amyloids may bind damaged or less fit spermatozoa and promote their clearance by 
phagocytic cells resident in the female genital tract. Interestingly, these same cell types are targeted 
for infection by several sexually transmitted viruses including EBOV, and the hypothesis that 
seminal amyloids may enhance their infection by a similar mechanism is untested. 
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Section 2.4 – Targeting amyloid fibrils 
Heterosexual sexual transmission of HIV-1 and some other sexually transmitted viruses 
appears to be a relatively rare event. While HIV-1 transmission is highly dependent on viral load, 
studies suggest that transmission probabilities range from 0.01% to 0.23% per act26. Because these 
rates are very low, especially in the context of the huge burden of HIV-1 disease, even modest 
decreases in these rates may have large impacts on prevention of HIV-1 transmission. Because 
seminal amyloids are able to greatly enhance viral infection in vitro, the development of compounds 
that reduce this enhancement effect has been explored. Many of these strategies interfere with 
amyloid formation, stability, interaction with viral particles, or a combination of these27. 
Many compounds have been explored to prevent the interaction of SEVI with viral particles, 
often by shielding the highly positive charge of the amyloid. Heparan sulfate and other polyanions 
have been shown to disrupt the interaction between SEVI and HIV-1 particles in addition to direct 
activity against HIV-111,28,29. Unfortunately, these molecules had detrimental effects in clinical 
settings due to induction of inflammatory responses that resulted in an increase in HIV acquisition30. 
A similar strategy is to treat cells with molecules that antagonize the interaction between SEVI and 
the polyanions on the cell surface such as heparan sulfate proteoglycan. Surfen, such an 
antagonist, inhibits both interactions between the amyloid and cellular membrane as well as 
between the amyloid and viral membrane31. Another strategy has involved use of molecular 
tweezers that specifically bind arginine and lysine residues, shielding their positive charge from the 
virion. These molecules inhibit enhanced HIV-1 infection both through this mechanism and through 
direct antiviral effects on HIV-1 and other viral membranes12. This strategy is particularly attractive 
as it acts on both the virion and a host factor, making it unlikely that the virus will be able to evolve 
resistance to this mechanism. 
Inhibition of the formation of precursor peptides into amyloid (e.g. PAP248-286 into SEVI 
fibrils) is a strategy that takes advantage of the observation that soluble peptides have no impact 
on viral infection. One such strategy is to design non-natural peptides that are able to interact with 
the amyloidogenic peptide but sterically block amyloid assembly. A computationally designed 
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peptide, WW61, was found to be able to prevent PAP248-286 from assembling into SEVI fibrils32. 
However, because fibrils are present in their amyloid state in semen33, such a strategy may not be 
viable to prevent enhancement of viral infection in vivo. Epigallocatechin-3-gallate (EGCG), an 
antioxidant isolated from green tea, has been shown to disassemble SEVI fibrils slowly (over the 
span of 1-2 days) and prevent formation of PAP248-286 peptides into fibrils34. Again, it is unclear 
whether this strategy would be viable in vivo over such a timescale. 
A final strategy is to remodel amyloid fibrils, either by disassembling the amyloid structure 
or by altering the conformation to one that does not enhance viral infection. In addition to EGCG 
described above, work has been done exploring the ability of disaggregase proteins to act upon 
amyloid substrates (Box 235). Hsp104, a yeast AAA+ protein, is able to both resolve and refold 
disordered protein aggregates and remodel amyloid fibrils36. It was found that Hsp104 is able to 
remodel SEVI, SEM1, and PAP85-120 amyloid fibrils in an ATP-dependent fashion to prevent 
enhancement of infection35. Interestingly, a mutant Hsp104 that was unable to hydrolyze ATP was 
still able to remodel the seminal amyloids into clusters that did not enhance HIV-1 infection35. This 
is particularly important because ATP is present at very low levels in the extracellular space. Thus, 
disaggregase proteins may represent a useful strategy for reducing the infection enhancement 
ability of amyloid fibrils. 
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Section 3.1 – Abstract 
The 2014 Western Africa Ebola virus (EBOV) epidemic was unprecedented in magnitude, 
infecting over 28,000 and causing over 11,000 deaths. During this outbreak, multiple instances of 
EBOV sexual transmission were reported, including cases where the infectious individual had 
recovered from EBOV disease months before transmission. Potential human host factors in EBOV 
sexual transmission remain unstudied. Several basic seminal amyloids, most notably semen-
derived enhancer of viral infection (SEVI), enhance in vitro infection by HIV and several other 
viruses. To test the ability of these peptides to enhance EBOV infection, viruses bearing the EBOV 
glycoprotein (EboGP) were preincubated with physiological concentrations of SEVI before infection 
of physiologically relevant cell lines and primary cells. Pre-incubation with SEVI significantly 
increased EboGP-mediated infectivity and replication in epithelium- and monocyte-derived cells. 
This enhancement was dependent upon amyloidogenesis and positive charge, and enhancement 
was observed with both viruses carrying EboGP and authentic EBOV. SEVI enhanced binding of 
virus to cells and markedly increased its subsequent internalization. SEVI also stimulated uptake 
of a fluid phase marker by macropinocytosis, a critical mechanism by which cells internalize EBOV. 
We report a previously unrecognized ability of SEVI to significantly alter viral physical properties 
critical for transmissibility by increasing the stability of EboGP-bearing recombinant viruses during 
incubation at elevated temperature and providing resistance to desiccation. Given the potential for 
EBOV sexual transmission to spark new transmission chains, these findings represent an important 
first interrogation of factors potentially important for this novel EBOV transmission route. 
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Section 3.2 – Significance Statement 
During the 2014-2016 Ebola outbreak, multiple instances of male-to-female sexual transmission of 
Ebola virus (EBOV) were reported. While relatively uncommon, EBOV sexual transmission 
presents a major public health concern, as these transmission events occurred months after 
recovery. Further, sexual transmission was linked to a resurgence of EBOV disease in Guinea, 
which had previously been declared Ebola-free. However, the role of host factors involved in sexual 
transmission remain unknown. We find that seminal amyloids are able to greatly enhance EBOV 
infection and alter the virion physical properties, stabilizing viral infectivity and protecting the virus 
from drying. These results suggest these seminal amyloids as possible targets for intervention to 
prevent EBOV sexual transmission and seeding new infection chains that reignite an outbreak.  
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Section 3.3 – Introduction 
The 2014-2016 Western Africa Ebola outbreak was the largest Ebola outbreak on record, 
causing more than 28,652 cases and killing 11,3251. Ebola virus [EBOV] disease (EVD) is primarily 
spread by contact with bodily fluids of an infected individual or a person who has died from EVD. 
Even after recovery from EVD, EBOV remains detectable in several anatomic locations and bodily 
fluids, including in semen2. Cohort studies of male EVD survivors demonstrated that infectious 
EBOV could be isolated from semen up to 82 days after EBOV onset3,4. The maximum recorded 
persistence of EBOV RNA in semen is 965 days, although the concordance between persistent 
RNA and infectious virus is unclear5. During the 2014-2016 EBOV outbreak, multiple cases of 
sexual transmission – some sparking new transmission chains – were reported in case reports 
supported by epidemiological and molecular evidence6–10. Transmission was reported from a male 
survivor 470 days after his EVD onset9. An epidemiological model of EBOV sexual transmission in 
Sierra Leone predicted that if survivors experienced even a 3-month infectious period, the outbreak 
would be extended by an average of 83 days11.  
EBOV tropism is broad12,13 and histological studies demonstrate a wide variety of cell types 
infected in vivo during infection12,14–16. It has been suggested that monocytes, macrophages, and 
dendritic cells in particular are important early targets for infection12,16–19. EBOV entry into cells is 
enhanced by interactions between the virion and cellular attachment factors that include C-type 
lectins (e.g. DC-SIGN and DC-SIGNR)20–24 and phosphatidylserine-binding molecules such as 
Tyro3 family members (e.g. Axl)25 and TIM-126. EBOV requires macropinocytosis as an uptake 
mechanism27–29, resulting in its trafficking to acidified endosomes where the glycoprotein is 
processed by cathepsin B/L proteases30. After processing, the glycoprotein interacts with its 
receptor Niemann-Pick C1 (NPC1) to effect fusion between the viral and endosomal 
membranes31-33. 
Screening of protein/peptide libraries derived from human semen identified peptides that 
dramatically enhance viral infection34. The most well-studied of these is PAP248-286, a highly basic 
39-amino acid cleavage product of prostatic acid phosphatase (PAP)35. While having no impact on 
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HIV-1 infection as a soluble peptide, PAP248-286 assembles into amyloid fibrils termed semen-
derived enhancer of viral infection (SEVI) which greatly increase HIV-1 infectivity35. Subsequent 
analyses have identified other amyloid fibrils in semen that enhance HIV-1 infection, including 
another cleavage product of PAP (PAP85-120)36 and fragments of semenogelin-1 and -2, 
components of the seminal coagulum37. Both positive charge and amyloid character are important 
for enhancement of HIV-1 infection by SEVI, as modified peptides without positive residues form 
amyloid fibrils with greatly diminished enhancement ability38. Anionic polymers such as dextran 
sulfate38 and molecular tweezers that bind positively charged amino acids39 inhibit SEVI’s 
enhancement effect, highlighting the importance of charge. Subsequent reports have identified 
enhancement roles for these fibrils for infection by SIV, CMV, and HSV-1, though the enhancement 
effects were generally lower for these viruses than those reported for HIV-140–42.  
A leading model of SEVI enhancement of infection posits that the highly positive charge of 
the amyloid fibrils reduces electrostatic repulsion between the negative charges of the virion and 
cellular membranes. For HIV-1, an increase in virus attached to the cell surface was detected upon 
pretreatment of the virus with SEVI relative to virus alone35. SEVI fibrils are endocytosed by cellular 
protrusions, but the role this plays in enhancement of viral infection is not known35. It has also been 
reported that fusion of the viral and cellular membranes is enhanced upon pretreatment of HIV-1 
with SEVI, though it is unclear whether SEVI enhances fusion per se or if increased 
attachment/binding results in an increase in downstream entry events35.  
The ability of sexual transmission to reignite an outbreak warrants examination of factors 
affecting EBOV sexual transmission. In this study, we addressed whether seminal amyloids 
enhanced EBOV infection in vitro. Our results indicate that SEVI and other seminal amyloid fibrils 
greatly enhanced infection mediated by the EBOV glycoprotein using both non-pathogenic EBOV 
surrogates and authentic EBOV. This enhanced infection retained requirements for EBOV infection 
including macropinocytic uptake and cathepsin processing. In addition, we identify a new potential 
role for seminal amyloid fibrils in enhancing viral stability after extended incubation at elevated 
temperature or upon desiccation.   
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Section 3.4 – Materials and Methods 
Viruses and cells. Recombinant VSV expressing the EBOV glycoprotein and mCherry (rVSV-
EboGP-mCherry) has been previously described43,44. To generate rVSV-EboGP-mCherry stocks, 
Vero CCL81 cells (gift from Susan Weiss, U. Pennsylvania) were infected at an MOI of 0.001 for 3 
days; clarified supernatant was buffered with 25 mM HEPES, aliquoted, frozen at -80°C, and titered 
by TCID50 on Vero CCL81 cells. EBOV/“Zaire 1995” (EBOV/H.sap-tc/COD/95/Kik-9510621) was 
used in authentic virus studies45. HeLa, A549, and THP1 cell lines and macrophages differentiated 
from purified human blood monocytes were used as target cells for infections. 293T cells were used 
for transfection. Samples obtained from the University of Pennsylvania Human Immunology Core 
are considered to be a secondary use of deidentified human specimens and are exempt via Title 
55 Part 46, Subpart A of 46.101 (b) of the Code of Federal Regulations. 293T, HeLa, and A549 
cells (ATCC) were maintained in DMEM with 4.5 g/L glucose and no sodium pyruvate 
supplemented with 10% FBS (Sigma). THP1 cells were maintained in RPMI-1640 supplemented 
with 10% FBS and 50 mM β-mercaptoethanol. Human monocyte-derived macrophages were 
maintained in RPMI-1640 with glutamine, 10% FBS, and penicillin/streptomycin, and were 
differentiated from peripheral blood monocytes by incubation in 20 μg/mL MCSF (Gemini) for 7 
days.  
 
Peptides and Fibrils. SEVI, SEVI-Ala, PAP85-120, SEM1, and SEM2 fibrils were generated by 
dissolving peptides (Keck Biotechnology Resource Laboratory, Yale University) in PBS, filtering 
through a 0.2 μm filter, seeding with 1% preformed amyloid, and incubating at 37°C with shaking 
at 1400 rpm35–37. Amyloid formation was confirmed by assessing thioflavin T fluorescence. Aliquots 
were stored at -80°C and working stocks kept at 4°C. Peptide sequences are available in 
Supplementary Table 3.1. 
 
Infection assays. rVSV-EboGP-mCherry was diluted into DMEM-10 alone or supplemented with 
amyloid fibrils or soluble peptides and incubated at 37°C for 15 minutes. 20 μL of the infection 
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mixture was added to each well of target cells in a 96-well plate (plated at 1.5e4 cells/well the 
previous day in 100 µL DMEM-10) and incubated at 37°C for 1 h, then the media was replaced with 
fresh DMEM-10 and incubated at 37°C for a total of 12 h. Cells infected in the presence of SEVI 
were harvested by trypsinization, fixed in 2% paraformaldehyde (PFA), and analyzed by flow 
cytometry for mCherry expression. For experiments containing amyloids other than SEVI, the cells 
were fixed, permeablized with 0.1% saponin in FACS buffer (1% BSA, 0.01% sodium azide in PBS), 
and stained for 1 h with a combination of 1:1000 mouse monoclonal anti-VSV(M) primary antibody 
(gift from Robert Doms, U. Pennsylvania) and 1:5000 goat anti-mouse secondary antibody labeled 
with AF488 (Life Technologies) before analysis by flow cytometry. For each experiment, the 
average of triplicate technical replicates was log-transformed, and transformed percents infection 
of biological replicates were compared by repeated measures ANOVA with post hoc analysis using 
false discovery rate analysis to correct for multiple comparisons (GraphPad Prism). Monocyte-
derived macrophages were treated with B18R (Abcam) for 24 h prior to as well as during infection 
to inhibit the interferon response. 
 
For authentic virus infections, peptides were diluted to 5-50 µg/ml and pre-incubated with EBOV 
for 15 minutes. HeLa cells were exposed to peptide/virus inoculum at an MOI of 2.0 or 0.2 PFU/cell 
for 1 h, after which peptide/virus inoculum was removed and fresh culture media added. At 24-48 
h post-infection, cells were formalin-fixed, removed from containment, and immunostained using 
the 13F6 antibody46 at 2 µg/ml. Infection was quantified using automated fluorescence microscopy 
as described47. 
 
Binding/Internalization assays. rVSV-EboGP-mCherry was pretreated with or without SEVI then 
bound to HeLa cells on ice. Cells were either lysed in 1% Triton for 10 minutes on ice after 1 h 
(binding) or warmed to 37°C for 1 h to allow viral internalization, washed 3x in PBS with Ca2+ and 
Mg2+, trypsinized for 10 minutes at 37°C, and lysed with 1% Triton for 10 minutes on ice 
(internalization). Lysates were separated on a 12% Criterion TGX gel, transferred to nitrocellulose 
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for 1 h, and blocked with TBS Odyssey Blocking Buffer (Li-Cor). Membranes were probed for VSV 
M (1:1000, Ab as above) and GAPDH (1:2000, rabbit polyclonal, Santa Cruz Biotechnology) in TBS 
Blocking Buffer/0.2% Tween simultaneously for 1 h, then with IRDye 800CW goat anti-mouse and 
IRDye 680RD goat anti-rabbit (1:15,000, Li-Cor) in TBS blocking buffer/0.2% Tween. Membranes 
were then analyzed by quantitative Western blotting by comparing VSV M signal to GAPDH signal 
for each sample. 
Virus-like particle generation. 293T cells were plated in 15 cm plates the day before transfection. 
Cells were transfected with 7.5 μg each of pCAGGS-EboGP, pCAGGS-VP40, and either pCAGGS-
VP40(luc) or pCAGGS-VP40(GFP) with polyethylenimine48. Supernatants were collected at 24 and 
48 h after transfection, concentrated through a 20% sucrose cushion by ultracentrifugation, 
resuspended in 1% BSA, 50 mM HEPES-buffered PBS, and frozen at -80°C until use. 
VLP binding assay. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before the 
assay and incubated on ice for 30 min prior to the experiment. SEVI fibrils were diluted to 35 μg/mL 
in DMEM-10 and mixed with 3 μL concentrated EBOV VLP (VP40-luc) and incubated at 37°C for 
10 min. 20 μL of the mixture was added to triplicate wells and spun at 1200g for 30 min at 4°C. 
After spinning, the cells were washed 5X with cold DMEM-10 and lysed with Bright-Glo luciferase 
assay buffer (Promega). Luciferase activity was read on a Luminoskan Ascent (Thermo) 10 minutes 
after addition of assay buffer, and after background subtraction, readings were normalized to 0 
μg/mL SEVI condition. Statistical significance was determined by paired t-test of log-transformed 
data (StataIC 14). 
VLP internalization assay. The VLP internalization assay was done similarly to what has been 
previously described49. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before 
the assay. Cells treated with EIPA were pretreated with 100 μM EIPA for 1 h prior to the beginning 
of the experiment and incubated on ice for 30 minutes prior to the beginning of the experiment. 
SEVI fibrils were diluted to 35 μg/mL in DMEM-10 and mixed with 2 μL EBOV VLP (VP40-GFP) 
and incubated at 37°C for 10 min. After incubation, 20 μL of this mixture was added to triplicate 
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wells and spun at 1200g for 30 min at 4°C. The plate was then shifted to 37°C for 1 h. The cells 
were then trypsinized, fixed in 2% PFA, and analyzed by flow cytometry for geometric mean 
fluorescence intensity in the GFP channel. Statistical significance was determined by repeated 
measured ANOVA with false discovery rate correction (GraphPad Prism). 
Dextran uptake assay. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before 
the assay. Cells treated with EIPA were pretreated with 100 μM EIPA for 1 h. Culture medium was 
removed from each well and replaced with indicated concentrations of SEVI diluted in DMEM-10 
with or without 100 μM EIPA in triplicate. The cells were incubated at 37°C for 20 minutes, then 2.5 
μL of 20 mg/mL FITC-dextran (70 kDa in DMSO, Invitrogen) was added to each well for 10 minutes 
at 37°C. Afterward, the medium was removed and replaced with 100 μL of PBS pH 4.9 to bleach 
any uninternalized FITC. Cells were trypsinized and fixed in 2% PFA, washed 3X with FACS buffer 
(1% BSA in PBS, 0.1% sodium azide) and analyzed by flow cytometry. Data were analyzed with 
FlowJo to determine geometric mean fluorescence intensity in the FITC channel. Statistical 
significance was assessed by linear regression analysis or repeated measures ANOVA with false 
discovery rate correction (GraphPad Prism). 
Inhibitor treatments. HeLa cells were plated in a 96-well plate at 1.5e4 cells/well the day before the 
assay. Cells treated with inhibitors [100 μM EIPA (Toronto Research Chemicals), 1 μM cytochalasin 
D (Cayman Chemical Company), 0.5 μM 17-hydroxywortmannin (Cayman Chemical Company), 
50 μM LY294002 (Cayman Chemical Company), 50 mM NH4Cl (Fisher), 10 μM Z-FF-FMK (EMD 
Biosciences), 10 μM leupeptin (Sigma), 10 μM E64 (EMD Biosciences), or 10 μM MDL28170 
(Calbiochem)] were pretreated for 1 h before infection. Cells were infected as described earlier. 
After 1 h of infection, the virus- and inhibitor-containing medium was removed and replaced with 
medium without inhibitor for the remainder of the incubation. Infections were harvested and 
analyzed for percent infection as described above. To test for cytotoxic effects, HeLa cells were 
treated with inhibitors for 2 h before assessment for viability by the CellTiter 96 AQueous One 
Solution Cell Proliferation assay kit (Promega) according to manufacturer instructions. 
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Virus stability analysis. rVSV-EboGP-mCherry was diluted from stock concentrations to 
concentrations of 1e7 TCID50/mL in artificial semen simulant, with or without SEVI fibrils or α-
synuclein fibrils (35 μg/mL). For thermal stability experiments, samples were taken immediately (0 
h timepoint) or after indicated times of incubation at 37°C in a thermocycler with heated lid to 
minimize evaporation. Samples were frozen at -80°C until titration by TCID50. For desiccation 
tolerance experiments, 10 μL of diluted virus in artificial semen simulant was spotted in the bottom 
of non-tissue-culture-treated 96-well plates and allowed to dry under laminar flow in a biosafety 
cabinet at room temperature for indicated lengths of time. For comparison, samples from the bulk 
liquid (maintained at room temperature in sealed tube) were taken at the initial timepoint and the 
last timepoint. Samples were immediately titered by TCID50 after addition of 200 μL of DMEM to 
recover virus from the dried samples. 
TCID50. Vero cells were plated the previous day at 1.5e4 cells/well in 96-well plates. Viral samples 
were serially diluted in serum-free DMEM then added in 8-fold replicate to 96-well plates. After 48-
72 h, wells were scored by presence/absence of viral replication as marked by fluorescent protein 
expression and cytopathic effects. TCID50/mL was calculated by the Spearman & Kärber 
algorithm50. Data were log-transformed and analyzed for statistical significance by nonlinear 
regression (GraphPad Prism).  
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Section 3.5 – Results 
Section 3.5.1 – Seminal amyloids enhance rVSV-EboGP-mCherry infection 
 The enhancement ability of seminal amyloids on EBOV glycoprotein-mediated infection 
was first assessed with a recombinant vesicular stomatitis virus expressing the EBOV glycoprotein 
(rVSV-EboGP-mCherry, Fig 3.1A). Recombinant or pseudotyped VSV systems have been widely 
used to explore the interactions of the EBOV glycoprotein and viral membrane with cells during 
entry due to faithful mimicry of the EBOV infection process in a BSL-2 environment 30,31,51,52. SEVI 
is the best studied of the seminal amyloids, having been the first characterized and having variants 
available to explore mechanistic details35,38. Chemically synthesized PAP248-286 peptides were 
assembled into SEVI amyloid fibrils and preincubated with rVSV-EboGP-mCherry at indicated 
concentrations. These mixtures were used to infect cell lines representing potential target cell types 
during EBOV sexual transmission, including epithelium-derived HeLa and A549 cells and 
monocyte-derived THP1 cells. Percent infection was measured by flow cytometry for the mCherry 
reporter. Preincubation of rVSV-EboGP-mCherry with SEVI resulted in a striking increase in 
infectivity by 16.9- to 20.5-fold for the cell lines analyzed at 35 μg/mL, the concentration of SEVI 
reported in human semen35 (Fig 3.1B-C). A 4.3-fold increase in output virus was observed in 
primary monocyte-derived macrophages, indicating that the enhancement effect was not limited to 
cell lines (Fig 3.1D). These experiments were done at low multiplicity of infection, when 
enhancement by SEVI has been characterized as most effective35. However, due to concerns of 
reproducibility with such low initial percent infection, most subsequent studies were done at higher 
MOI with a concomitant decrease in fold enhancement. 
 Other amyloidogenic peptides derived from the seminal proteins prostatic acid 
phosphatase (PAP85-120), semenogelin-1 (SEM1), and semenogelin-2 (SEM2) have been 
reported to enhance viral infection36,37,41. To determine whether these other amyloid fibrils enhance 
infection mediated by the EBOV glycoprotein, rVSV-EboGP-mCherry was preincubated with 
physiological concentrations of SEVI fibrils, PAP85-120 fibrils, representative SEM1 fibrils, or 
representative SEM2 fibrils and used to infect HeLa cells (MOI 3). Because of background for these 
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other peptides in the mCherry channel (Fig 3.S1), infection was quantified by flow cytometry after 
staining for VSV M protein. We observed that all four amyloid peptides significantly increased 
infection by rVSV-EboGP-mCherry, with the SEM1 amyloid fibrils exhibiting the highest fold 
increase of 20.3-fold (Fig 3.1E). The SEM2 and PAP85-120 peptides also significantly enhanced 
infection by the recombinant virus by 9.2- and 4.2-fold, respectively. These results demonstrate 
that rVSV-EboGP-mCherry infection is enhanced, to differing degrees, by four amyloid fibrils 
present in human semen. 
SEVI-mediated enhancement of infection has been previously found to be dependent upon 
the charge and amyloid character of the peptides35,38. To determine whether SEVI-mediated 
enhancement of rVSV-EboGP-mCherry maintains similar specific requirements, rVSV-EboGP-
mCherry was pretreated with SEVI fibrils, SEVI fibrils in which the positively-charged amino acids 
have been replaced with alanine (SEVI-Ala)38, or freshly dissolved PAP248-286. HeLa cells were 
infected with the virus-peptide mixtures (MOI 3) and infection was analyzed by flow cytometry for 
mCherry expression. Unlike SEVI, which effected a 7.5-fold enhancement of rVSV-EboGP-
mCherry infection at this MOI, infection in the presence of SEVI-Ala or soluble PAP248-286-treated 
virus did not differ from rVSV-EboGP-mCherry alone (Fig 3.1F). These results indicate that much 
like enhancement of HIV-1 infection, the positive charge and amyloid character of the peptide are 
both critical for rVSV-EboGP-mCherry enhancement. 
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Section 3.5.2 – SEVI enhances EBOV VLP binding and internalization 
 To characterize the mechanism of SEVI-mediated enhancement of Ebola glycoprotein-
mediated infection, binding and internalization experiments were performed. To assess impacts on 
binding, rVSV-EboGP-mCherry was preincubated with SEVI before binding to HeLa cells on ice for 
1 h. Afterward, the cells were lysed on ice. Lysates were analyzed by quantitative Western blotting, 
probing for VSV M to assess quantity of virus present using GAPDH as a loading control. Signal in 
the presence of SEVI was compared to rVSV-EboGP-mCherry bound in the absence of SEVI. Only 
a modest increase in binding (1.5- to 2-fold) that saturated below the concentrations of SEVI tested 
was observed (Fig 3.2A). Binding was further quantified with a binding assay using EBOV virus-
like particles (VLPs). These particles show filamentous morphology and replicate steps of the 
EBOV entry process28,53–55. VLPs with a luciferase reporter were preincubated with SEVI and bound 
to HeLa cells at 4°C with centrifugation, then the cells were washed, lysed in luciferase assay 
buffer, and luminescence recorded. In agreement with previous results, an approximately 2-fold 
increase in binding was observed in the presence of SEVI (Fig 3.S2A). 
 Internalization by macropinocytosis is essential for EBOV entry, therefore the impact of 
SEVI on internalization was also analyzed in a similar way. After binding to cells on ice, the cells 
were shifted to 37°C for an additional hour to permit internalization. The cells were then washed 
and trypsinized to remove bound but uninternalized virus, then lysed and analyzed by Western 
blotting. Strikingly, quantitative Western blotting analysis demonstrated a linear (R2=0.9894) dose-
dependent relationship between SEVI preincubation concentration and relative internalization, with 
physiological concentrations of SEVI resulting in an approximately 10-fold increase in 
internalization of rVSV-EboGP-mCherry after background subtraction (Fig 3.2B). To further confirm 
this finding, EBOV VLPs labeled with GFP were preincubated with SEVI and bound to HeLa cells 
on ice then shifted to 37°C. After trypsinization, cells were analyzed by flow cytometry for GFP 
signal. While less quantitative than the blotting analysis, an increase in geometric mean 
fluorescence intensity of approximately 25% was observed in the presence of SEVI, suggesting 
that cells internalized a significantly higher quantity of VLPs when pretreated with SEVI than without 
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pretreatment (Fig 3.S2B). This effect was ablated by the macropinocytosis inhibitor N-(ethyl-N-
isopropyl)-amiloride (EIPA), suggesting efficient removal of bound VLPs from the cell surface.  
 The ability of SEVI to enhance viral internalization has not been previously reported. 
Previous reports have shown that SEVI is internalized into cells, raising the possibility it may induce 
endocytosis35. To explore the ability of SEVI to modulate macropinocytosis in a virus-free 
environment, HeLa cells were incubated at 37°C with different concentrations of SEVI for 20 
minutes before the addition of a macropinocytic marker molecule FITC-dextran for 10 minutes. The 
cells were treated with PBS pH 4.9 to bleach any uninternalized FITC and trypsinized, and then 
geometric mean fluorescence intensity (gMFI) was determined by flow cytometry. A linear 
relationship (R2 = 0.9799) was observed between SEVI concentration and gMFI, with the highest 
concentrations of SEVI leading to a 3.7-fold increase in macropinocytic uptake (Fig 3.2C). This 
increase in fluorescent intensity was ablated in the presence of EIPA, indicating efficient bleaching 
of bound FITC signal and a specificity of macropinocytosis for uptake (Fig 3.2C). The enhanced 
FITC-dextran internalization depended upon the charge and amyloid character of the SEVI peptide, 
as SEVI-Ala and soluble PAP248-286 peptide treatment showed no increase in dextran uptake 
(Fig 3.2D). These results provide evidence for the ability of SEVI to promote macropinocytic uptake 
to increase internalization of EBOV particles. 
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Figure 3.2. SEVI enhances rVSV-EboGP-mCherry binding, internalization, and cellular 
macropinocytosis. 8 
A. HeLa cells were prechilled and treated with rVSV-EboGP-mCherry pretreated with or without 
SEVI fibrils. Cells were lysed and the ratio of VSV M:GAPDH signal was compared to untreated 
control by quantitative Western blotting; n=3, mean ± SEM. B. HeLa cells were prechilled and 
treated with rVSV-EboGP-mCherry pretreated with or without SEVI fibrils. After 1 h, the cells were 
shifted to 37°C to allow internalization. Cells were washed, trypsinized, and lysed, and the ratio 
of VSV M:GAPDH signal was compared to untreated control by quantitative Western blotting; 
n=3, mean ± SEM. C. HeLa cells were treated with different concentrations of SEVI fibrils then 
treated with dextran-FITC in the presence or absence of EIPA. Geometric mean fluorescent 
intensity was measured by flow cytometry and normalized; n=3, mean ± SEM. **p<0.01 by linear 
regression analysis. D. HeLa cells were treated with or without 35 μg/mL SEVI fibrils, SEVI-Ala 
fibrils, or soluble PAP248-286 then 70 kDa dextran-FITC. n=3, mean ± SEM. **p≤0.01 by ANOVA 
of gMFI values. E. Normalized percents infection of HeLa cells pretreated with macropinocytosis 
inhibitors and infected with rVSV-EboGP-mCherry (MOI 5) with or without 35 μg/mL SEVI fibrils. 
F. Normalized percents infection of HeLa cells pretreated with DMEM-10 alone or supplemented 
with cathepsin inhibitors infected with rVSV-EboGP-mCherry (MOI 5) pretreated with or without 
35 μg/mL SEVI fibrils. For both E and F: n=3, mean ± SEM, *p<0.05, **p<0.01, ***p<0.001 by 
two-factor repeated measures ANOVA.  
2B 2A 
2E 2F 
2C 2D 
 
51 
Section 3.5.3 – SEVI-mediated enhancement maintains EBOV entry requirements 
 Following binding of the virus to the cell, EBOV particles are endocytosed by 
macropinocytosis and traffic through the endosomal system where cellular cathepsins process the 
glycoprotein, enabling an interaction of the glycoprotein with its receptor to initiate fusion of the viral 
and cellular membranes and infection56. To determine whether the fibril-enhanced infection 
diverges from the canonical EBOV entry pathway, cells were infected with rVSV-EboGP-mCherry 
in the presence or absence of inhibitors of macropinocytosis or cathepsin activity, with or without 
preincubation of the virus with SEVI. No cytotoxic effects were observed with any of these inhibitors 
(Fig 3.S3). To inhibit macropinocytosis, HeLa cells were treated with EIPA, cytochalasin D, 17β-
hydroxywortmannin, or LY294002 for 1 h before and 1 h during infection with the virus-peptide 
mixture (MOI 5). While infection by rVSV-EboGP-mCherry was enhanced by SEVI in this 
experiment in the absence of inhibitor, all macropinocytosis inhibitors equally reduced infection by 
5- to 10-fold in both the absence and presence of SEVI. These results indicate that macropinocytic 
entry is not bypassed in the presence of SEVI and that infection maintains this cellular requirement 
for EBOV glycoprotein-dependent infection (Fig 3.2E). Similarly, inhibitors of cathepsin activity, 
including ammonium chloride, E64, Z-FF-FMK, leupeptin, and MDL28170, abrogated infection of 
HeLa cells by 10- to 20-fold in both the presence and absence of physiological levels of SEVI (Fig 
3.2F). These results imply that while SEVI enhances infection, it does not permit the virus to bypass 
critical cellular requirements for rVSV-EboGP-mCherry entry.  
 
Section 3.5.4 – SEVI alters rVSV-EboGP-mCherry physical characteristics 
 We next hypothesized that seminal amyloid fibrils could affect the physical characteristics 
of the virus, which may impact transmissibility. To determine if the interaction of viral particles with 
amyloid fibrils alters the physical characteristics of the virus, we analyzed the effects of thermal and 
chemical stressors on viral infectivity. Whether SEVI pretreatment impacts rVSV-EboGP-mCherry 
stability over time was assessed by incubation of rVSV-EboGP-mCherry with or without physiologic 
SEVI concentrations in artificial semen simulant57 for various lengths of time at 37°C. Artificial 
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semen simulant is designed to mimic the chemical composition of semen and contains 5 mg/mL 
BSA, making any nonspecific effects of additional protein (e.g. amyloids or peptides) unlikely. At 
each timepoint, the titer of virus was determined by TCID50 on Vero cells. Values were normalized 
to the starting titer for each condition, log-transformed, and analyzed by nonlinear regression. 
Strikingly, the presence of SEVI promoted increased viral viability relative to virus alone (p=0.0029). 
The normalized titer of virus incubated in the presence of SEVI was approximately 17-fold higher 
than that of virus incubated in semen simulant alone after 36 h (Fig 3.3A). This enhancement in 
stability required the positive charge and amyloid character of SEVI, as SEVI-Ala and PAP248-286 
had no effect on stability (Fig 3.3A). Further, addition of SEVI immediately before titration after 
incubation without SEVI was unable to rescue the effect, suggesting that SEVI exerts its stabilizing 
effects during the incubation itself and independently from its infection enhancement ability (Fig 
3.3A, 0 μg/mL SEVI+35 μg/mL SEVI). To test whether SEVI promoted resistance to oxidative 
stress, we analyzed the ability of rVSV-EboGP-mCherry to resist exposure to dilute concentrations 
of chlorine bleach for one minute. Unlike the results found with viral infectivity during prolonged 
incubation, SEVI did not enhance the ability of rVSV-EboGP-mCherry to withstand oxidative stress 
by chlorine bleach, with equivalent decreases in titer observed both in the presence and absence 
of SEVI (Fig 3.S4).  
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Figure 3.3. SEVI alters rVSV-EboGP-mCherry physical characteristics.9  
A. rVSV-EboGP-mCherry was incubated at 37°C in artificial semen simulant with or without 35 
μg/mL SEVI fibrils, SEVI-Ala fibrils, or PAP248-286 peptide and titered by TCID50 on Vero cells. 
For the 0 μg/mL+35 μg/mL SEVI condition, SEVI was added immediately before titration after 
incubation without. Data were normalized to the 0 h timepoint independently for the conditions 
with or without SEVI and fit to one-step decay model; n=3, mean ± SEM. B. rVSV-EboGP-
mCherry was diluted in artificial semen simulant with or without 35 µg/mL SEVI fibrils and dried 
under laminar flow before rehydration and titration by TCID50 on Vero cells. Data were normalized 
to the 0 h timepoint independently for the conditions with or without SEVI and fit to plateau 
followed by one-step decay model; n=3, mean ± SEM. 
3A 
3B 
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Lastly, we assessed whether the presence of SEVI fibrils could improve desiccation 
tolerance; as enveloped viruses, EBOV and rVSV-EboGP-mCherry are sensitive to drying. rVSV-
EboGP-mCherry was diluted in artificial semen simulant in the presence or absence of 
physiological concentrations of SEVI. Samples were maintained in bulk liquid or spotted into 96-
well plates (10 μL) and allowed to air dry. Samples were taken immediately (0 h) or after varying 
lengths of time drying under laminar flow at room temperature. Dried samples were rehydrated with 
200 μL of DMEM and infectivity was quantified by TCID50. Samples were also taken at 6 h from 
bulk liquid kept within a sealed tube to assess independently any effects of incubation at room 
temperature. TCID50/mL measurements were normalized to the initial timepoint for each and fitted 
to a plateau-one phase decay model, which reflects the lag in viral decay until after the liquid has 
evaporated. After 6 h of incubation, the normalized titer of virus desiccated in the presence of SEVI 
was approximately 10-fold lower than in its absence (Fig 3.3B). Notably, over this timescale at room 
temperature, there was no relative difference in viral titer between virus incubated in the presence 
or absence of SEVI in bulk liquid (p=0.10), suggesting the observed effects are actually due to 
desiccation and not temperature-induced decay (Fig 3.S5). Again, addition of SEVI immediately 
before titration after desiccation in its absence had no effect on desiccation kinetics (Fig 3.3B, 0 
μg/mL SEVI+35 μg/mL SEVI). This result indicates that SEVI promotes viral viability after 
desiccation and rehydration. To better understand the mechanism of SEVI-mediated desiccation 
tolerance, rVSV-EboGP-mCherry was also incubated with SEVI-Ala and PAP248-286. While 
PAP248-286 had no effect on desiccation tolerance, SEVI-Ala unexpectedly increased viral stability 
to the same extent as SEVI under these conditions. To determine if the presence of any amyloid 
could give this effect, rVSV-EboGP-mCherry was dried for 6 h in the presence of an equivalent 
mass of α-synuclein fibrils, which play a role in Parkinson’s disease pathogenesis58. No stabilizing 
effect was seen over incubation in semen simulant alone, suggesting that not all amyloids have 
this property (Fig 3.S6). Overall, these results indicate a previously unreported ability of seminal 
amyloid fibrils to stabilize viral infectivity, even after incubation at elevated temperatures over time 
or desiccation. 
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Section 3.5.5 – Seminal amyloids enhance infection by authentic EBOV 
 To confirm that the SEVI enhancement of rVSV-EboGP-mCherry faithfully mimics infection 
by authentic EBOV, HeLa cells were infected with EBOV after preincubation with various 
concentrations of SEVI fibrils. Preincubation of EBOV with SEVI led to a dose-dependent 
enhancement of infection similar to that observed with rVSV-EBOV-mCherry, resulting in a 28.9-
fold increase in infection after 24 h at the physiologic concentration of SEVI (MOI 0.2) (Fig 3.4A). 
As with EboGP-mediated VSV infection, the EBOV infection enhancement was dependent upon 
the charge and amyloid nature of the fibrils. In contrast to a 22.8-fold increase in infection observed 
in the presence of SEVI fibrils in this experiment, EBOV infection (MOI 2) was not enhanced by 
SEVI-Ala fibrils or soluble PAP248-286 (Fig 3.4B). Preincubation of EBOV with the other seminal 
peptides also enhanced infection at 24 h by 37.2-fold for PAP85-120 fibrils, 34.3-fold for SEM1 
fibrils, and 41.3-fold for SEM2 fibrils (all 35 μg/mL, MOI 2), in agreement with the results observed 
for rVSV-EBOV-mCherry (Fig 3.4C, 3.1E). 
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Figure 3.4. Seminal amyloids enhance EBOV infection. 10  
A. Normalized infection of HeLa cells infected with EBOV (MOI 0.2) preincubated with increasing 
concentrations of SEVI fibrils; n=2, mean ± SEM. B. Normalized infection of HeLa cells infected 
with EBOV (MOI 2) pretreated with or without 35 μg/mL SEVI fibrils, SEVI-Ala fibrils, or soluble 
PAP248-286; n=2, mean ± SEM. C. Normalized infection of HeLa cells infected with EBOV (MOI 
2) pretreated with or without 35 μg/mL SEVI fibrils, PAP85-120 fibrils, SEM1 fibrils, or SEM2 fibrils; 
n=2, mean ± SEM. 
 
4A 
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Section 3.6 – Discussion 
Reports of EBOV sexual transmission during the West Africa Ebola epidemic, though rare, 
are backed by strong epidemiological and/or molecular evidence6–10. Male-to-female transmission 
of persistent virus has been linked to resurgence of EBOV, but factors potentially involved in EBOV 
sexual transmission have not been characterized. This report provides evidence that seminal 
amyloid fibrils, a ubiquitous component of semen in healthy individuals, enhance in vitro infection 
by both an EBOV surrogate system and authentic EBOV. These fibrils act in a conformation- and 
charge-dependent manner to increase infection by increasing virion binding to host cells and 
enhancing macropinocytotic uptake. Further, we find that these fibrils act to protect virions from 
stresses potentially encountered during transmission, including thermal degradation and 
desiccation. 
 Ebola sexual transmission presented a significant and novel public health problem during 
and following the West Africa Ebola epidemic. Though rare and likely mitigated by public health 
agencies’ safe sex education initiatives, it has become apparent that semen of individuals with 
persistent EBOV is a potentially important vehicle to consider for EBOV transmission. For a 
successful male-to-female sexual transmission event, EBOV present in semen must either infect 
or cross the vaginal epithelium. Recent studies demonstrate that EBOV is able to infect the vaginal 
epithelium in guinea pig models59. Notably, the amount of infectious virus in semen has been 
difficult to determine, but at late time points is likely much lower than that in bodily fluids during 
acute illness. Prior studies on HIV indicate that the enhancement effect of SEVI is greatest with 
very low viral inoculums35; therefore, the effect of SEVI may be disproportionately important in 
EBOV sexual transmission as seminal viral titers wane. Animal models have suggested that 
macrophages and dendritic cells are early targets of the virus12,16–19. Our results indicate that 
seminal amyloids enhance infection of epithelial and monocytic cells and subsequent viral 
replication and thus could impact early events in sexual transmission. These cells express 
numerous attachment factors that increase the efficiency of infection by EBOV, including DC-SIGN. 
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Whether SEVI permits EBOV to bypass this dependence upon attachment factors or synergistically 
enhances attachment is not known and worth further study. 
In addition, our results demonstrate that amyloids impart resistance of the virus to 
potentially relevant environmental stresses, including extended incubations at physiological 
temperatures and desiccation. The ability of environmental factors to affect virion properties and 
infectivity is seen in other systems. As an example, recent studies have found that bacterial 
lipopolysaccharide (LPS) induces a conformational change in the poliovirus capsid, increasing virus 
binding to its cellular receptor and enhancing the stability of the virion60. These findings are similar 
to those we now report regarding the interaction of an enveloped virus and seminal amyloid fibrils. 
After binding to SEVI, rVSV-EboGP-mCherry binding, internalization, and tolerance to 
environmental stresses increase. The mechanism for this enhanced environmental resistance is 
unclear, but could involve retention of water molecules by the large amyloid fibrils to create a 
microenvironment surrounding the virions that is relatively resistant to changes in the larger-scale 
environment. The exact characteristics necessary for desiccation tolerance are unclear given the 
unexpected ability of SEVI and SEVI-Ala to enhance tolerance while another amyloid did not. 
Future experiments may involve exploration of the enhancement properties of a wider array of 
amyloids, as well as testing other viruses such as HIV-1. Resistance to environmental factors may 
be important to consider when assessing the ability of semen to remain infective over time. 
Moreover, the seminal amyloids may represent prophylactic drug targets, as strategies to 
disassemble the amyloids have been investigated34. 
 Since the identification of seminal amyloid fibrils as enhancers of HIV-1 infection in 2007, 
infection by several viruses with sexual transmission routes have been found to also be enhanced 
by SEVI. While not all sexually transmitted viruses are enhanced – notably, Zika virus is not 
enhanced appreciably by SEVI despite reports of Zika virus sexual transmission, potentially 
because of the dense Zika virus glycoprotein structure (Fig 4.1) – enhancement of infection by 
these viruses may represent a common target for intervention. Mechanistically, enhancement by 
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seminal amyloids has been proposed to enhance binding of the virus to the cell by alleviating 
repulsive interactions between the viral and cell membranes. Our results suggest that its effect on 
binding is modest, but SEVI stimulates macropinocytosis to increase viral internalization in addition 
to changing the physical properties of the virion (Fig 3.5). The enhancement of infection of primary 
monocyte-derived macrophages, as well as the striking increases in macropinocytosis observed in 
this study, are reminiscent of a recent report in which clearance of sperm cells by macrophages is 
enhanced by seminal amyloids61. Parallels between the clearance of spermatocytes by 
macrophages stimulated to engulf the cells by phagocytosis, and internalization of EBOV by 
phagocytic cells via a similar uptake mechanism are particularly intriguing. 
 An important limitation of the present study is the inability to study this phenomenon in an 
in vivo model, as no model for EBOV sexual transmission of persistent virus exists, and the 
challenges associated with developing one are considerable. However, seminal fibrils may 
represent an intriguing prophylactic target since agents that affect fibril stability or formation may 
target increased infectivity at a cellular level as well as enhanced viral stability ex vivo. Altogether, 
these findings represent the first analysis of molecular factors potentially involved in EBOV sexual 
transmission and may promote further study of this novel transmission route of an important human 
pathogen. 
Figure 3.5. Model of SEVI-mediated enhancement of EBOV infection.11 
 
60 
Section 3.8 – Supplemental Information  
 
Supplementary Table 3.1. Peptide Sequences 
SEVI GIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMY 
SEVI-Ala GIHAQAEASALQGGVLVNEILNHMAAATQIPSYAALIMY 
PAP85-120 IRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNL 
SEM1 (45–107) GQHYSGQKGKQQTESKGSFSIQYTYHVDANDHDQSRKSQQYDLNALHKTTKSQRHLGGSQQLL 
SEM2 (49-107) GQKDQQHTKSKGSFSIQHTYHVDINDHDWTRKSQQYDLNALHKATKSKQHLGGSQQLL 
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Figure 3.S1. SEM1 and PAP85-120 exhibit autofluorescence in the mCherry channel. 13 
HeLa cells were treated with seminal amyloids and autofluorescence was measured by flow 
cytometry. The percentage of cells in the 610_20 Green gate indicates background 
autofluorescence.  
S2B S2A 
Figure 3.S2. SEVI enhances VLP binding and internalization. 12 
A. HeLa cells were prechilled and treated with EBOV VLPs (VP40-luc) pretreated with or without 
35 μg/mL SEVI fibrils. After spinfection, cell-associated luciferase signal was determined and 
normalized; n=3, mean ± SEM. **p<0.01 by paired t test. B. HeLa cells were prechilled and treated 
with EBOV VLPs (VP40-GFP) pretreated with or without 35 μg/mL SEVI fibrils. After allowing 
internalization, cells were analyzed for geometric mean fluorescence intensity of GFP. *p<0.05, 
***p<0.001 by repeated measures ANOVA. 
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Figure 3.S3. Macropinocytosis and cathepsin inhibitors do not exhibit cytotoxicity. 14  
HeLa cells were treated for 2 h with inhibitors in concentrations as described in Materials and 
Methods then cell viability was assessed by the CellTiter 96 AQueous One Solution Cell 
Proliferation assay. n=2, mean±SD. 
Figure 3.S4. SEVI does not promote increased stability following treatment with dilute bleach 15 
rVSV-EboGP-mCherry was diluted in DMEM-10 alone or supplemented with 35 μg/mL SEVI 
fibrils and treated with PBS or chlorine bleach diluted in PBS for a final concentration of 0.005% 
hypochlorite for 1 minute. The samples were then neutralized with sodium thiosulfate (10-fold 
excess of 0.01% solution) and titered by TCID50 on Vero cells. n=1, mean±SD. 
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Figure 3.S5. No differential thermal degradation occurs over six hours at room temperature in the 
presence or absence of SEVI.17 
 rVSV-EboGP-mCherry was diluted in artificial semen simulant alone or supplemented with 35 
µg/mL SEVI fibrils and titered either immediately or after six hours of incubation in a sealed tube at 
room temperature by TCID50 on Vero cells. p=0.10 by paired t test. 
Figure 3.S6. α-synuclein does not enhance rVSV-EboGP-mCherry desiccation tolerance.16 
rVSV-EboGP-mCherry was incubated at 37°C in artificial semen simulant with or without 35 μg/mL 
SEVI fibrils and titered by TCID50 on Vero cells. n=1. 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
Section 4.1 – Summary 
 Sexual transmission of persistent EBOV during the unprecedented 2014 Ebola epidemic 
represents an avenue by which outbreak control can be compromised. Despite the major public 
health problem that this presents, very little is known about the mechanisms involved in EBOV 
sexual transmission. This work is the first to study the role of host factors involved in EBOV sexual 
transmission at a molecular level. 
 Seminal amyloids, typified by SEVI, have been shown to greatly enhance the ability of 
HIV-1 and other viruses to infect cells in vitro. This work demonstrates that SEVI and other seminal 
amyloids are able to greatly enhance infection not only by a recombinant virus vector bearing the 
EBOV glycoprotein, but also by authentic EBOV in experiments conducted under Biosafety Level 
4 conditions. This enhancement occurs in multiple cell types, including epithelium-derived cell lines, 
a monocyte-derived cell line, and primary monocyte-derived macrophages.  
 At a molecular level, SEVI appears to enhance infection by rVSV-EboGP-mCherry by 
enhancement of entry. Similar to effects on other viruses including HIV-1, SEVI induces a modest 
increase in binding of the virus to the cell. However, this work shows a novel function of SEVI to 
greatly increase internalization of the virus into the cell. SEVI accomplishes this function by 
enhancing macropinocytosis in a dose-dependent manner. After the virus is internalized by this 
critical pathway, it appears to follow the typical EBOV entry process and maintains requirements 
for cathepsin processing of its glycoprotein.  
 This work demonstrates further novel functions for SEVI in viral stability. As an enveloped 
virus, EBOV (and the recombinant VSV) are sensitive to prolonged incubations at physiologic 
temperature as well as desiccation. Incubation of virus with SEVI instills additional stability in both 
situations, suggesting that seminal amyloid fibrils may increase viral infectivity under adverse 
environmental conditions. 
 The mechanistic details for SEVI-mediated enhancement of infection and stability were 
also explored. Much like the results observed for HIV-1 enhancement, enhancement of rVSV-
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EboGP-mCherry and EBOV infection required that SEVI maintain its positive charge as well as its 
amyloid character. Uncharged and soluble forms of SEVI were unable to increase macropinocytic 
uptake in cells. Similarly, only SEVI fibrils were able to enhance stability at physiologic temperature, 
with uncharged and unpolymerized forms showing no benefit over virus alone. In contrast, fibrils 
with positive residues replaced by alanine were able to instill protection from desiccation to the 
same degree as wild type SEVI fibrils, while soluble peptide had no effect.  
 Altogether, these findings indicate that amyloid fibrils are potentially able to enhance EBOV 
by two distinct mechanisms. At a molecular level, SEVI enhances infection by increasing binding 
and internalization. In an environmental context, SEVI enhances the ability of the virus to withstand 
environmental stresses, which may permit increased transmissibility.  
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Section 4.2 – Future directions 
 The identification of seminal amyloids as a pro-viral component of semen presents 
numerous avenues for future research. While this work has given insight into some mechanistic 
details regarding the SEVI-EBOV interaction, further study would elucidate a number of factors that 
remain unclear. 
Section 4.2.1 – Ex vivo infections 
 The first and perhaps most straightforward next step would be to determine if amyloid fibrils 
endogenously present in semen enhance infection and stability of rVSV-EboGP-mCherry. 
Protocols for infection as well as for removing seminal amyloids from seminal plasma exist1,2. Thus, 
the ability of semen to enhance infection and stability can be compared to semen devoid of amyloid 
fibrils. Collaborating with the Penn Medicine Division of Reproductive Endocrinology and Infertility 
for seminal samples, preliminary results suggest that semen does in fact enhance rVSV-EboGP-
mCherry infection. To further explore the enhancement effect in a model that may better reflect 
EBOV sexual transmission, vaginal explant models can be infected with either rVSV-EboGP-
mCherry or EBOV in the presence and absence of SEVI. The microenvironment in tissue may be 
significantly different from that in a culture plate, especially given the diversity of cells in tissue 
compared to clonal cell lines. These studies may give insight into the ability of seminal amyloids to 
enhance infection of a specific subset of cells, which would perhaps mirror the results of 
experimental animal infections that showed early and sustained infection of cells including DCs and 
macrophages. Alternatively, the enhanced infection seen in epithelium-derived cell lines lends 
credence to a hypothesis that the virus may be able to replicate in vaginal epithelial cells that form 
a barrier, establish local infection, then spread to other cell types. Notably, vaginal epithelial cells 
are infected in an acute EBOV model in guinea pigs3. No experiments have been done with explant 
models and no animal EBOV sexual transmission models exist, leaving the expected results for 
these experiments up for conjecture. 
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Section 4.2.2 – Enhancement in the context of other viruses 
 While infection by numerous sexually transmitted viruses is enhanced by SEVI, it does not 
appear to be universal. Zika virus (ZIKV), which was responsible for a pandemic across the 
Americas marked by an uptick in birth defects including microcephaly, has been demonstrated to 
be transmitted sexually in addition to its much more common mosquito transmission route. ZIKV 
MR766 (Figure 4.1) and ZIKV Mex 2-81 (data not shown) infection do not appear to be enhanced 
by SEVI nearly to the same degree as rVSV-EboGP-mCherry, EBOV, or HIV-1. Because the 
mechanism of SEVI-mediated enhancement is hypothesized to be glycoprotein-independent, this 
result would seem to be contrary to current models. However, cryo-electron microscopy has been 
used to generate models of ZIKV virions that show very little plasma membrane area not occluded 
by the E glycoprotein4. Other viruses (including EBOV) have a lower density of glycoprotein on the 
virion surface; HIV-1 in particular is notable for its very low density of glycoprotein, with as few as 
7-14 spikes being present per virion5–7. Thus, enhancement may not occur with ZIKV due to the 
inability of amyloid fibrils to effectively contact the virion membrane. It is unclear, and would be 
worth testing, whether ZIKV would exhibit increased stability and desiccation tolerance as does 
rVSV-EboGP-mCherry since infection is not enhanced. The ability of SEVI-Ala to promote 
desiccation tolerance (Fig 3.3B) 
suggests that an electrostatic 
interaction may not be required. It 
would also be interesting to 
assess whether SEVI enhances 
stability of other viruses whose 
infection is enhanced by the fibrils, 
especially HIV-1. Comparing the 
effects on stability may give clues 
to the mechanism of action of the 
fibrils for stability promotion. 
Figure 4.1. SEVI does not dramatically increase ZIKV 
infection.18  
ZIKV was incubated with SEVI at different concentrations for 
15 minutes before infection of A549 cells. Infection was 
quantified by immunostaining and flow cytometry. n=1.
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Section 4.2.3 – Stabilization against other environmental factors 
 The ability of SEVI to promote resistance to some forms of environmental stress raises the 
possibility that it may enhance resistance to others. Semen contains proteases and antibodies that 
may inhibit viral infection. It is possible that amyloids could bind to viral particles and physically 
occlude proteases and antibodies from respectively cleaving or neutralizing the virus. To test the 
hypothesis that SEVI could protect virus from proteolysis, rVSV-EboGP-mCherry was treated with 
tryspin or proteinase K for 30 minutes at 37°C with the intention of determining whether SEVI would 
reduce the sensitivity of the virus to proteolytic inactivation. However, under the conditions tested, 
no loss in infectivity was observed after protease treatment. It is unclear whether EboGP is sensitive 
to digestion by these enzymes. To more directly test the hypothesis, protocols assessing seminal 
protease activity could be adapted for use in a viral setting8.  
SEVI has been previously described to reduce the sensitivity of cytomegalovirus (CMV) to 
neutralizing antibodies, though extensive characterization of the effect was not completed9. To 
assess whether SEVI impacts neutralization sensitivity of EboGP, rVSV-EboGP-mCherry was 
incubated with two different neutralizing anti-EboGP antibodies with or without SEVI for 1 h at 37°C 
then used to infect cells. Normalized infection values were used to calculate IC50 values in the 
presence and absence of SEVI (Figure 4.2). There was no difference between IC50 values in the 
presence or absence of SEVI, suggesting no protective effect. It is unclear what difference there is 
between the CMV and rVSV-EboGP-mCherry results except that the EboGP neutralization 
capacity was tested at numerous concentrations, while the CMV data were a single point and may 
not have been representative. It is also possible that the CMV glycoprotein targeted (gH) interacts 
with SEVI in some way that renders it less sensitive to neutralization. Studies testing a wider array 
of anti-gH antibodies targeting different domains of the glycoprotein could help to clarify the ability 
of SEVI to enhance neutralization sensitivity. Further, both anti-EboGP antibodies targeted the 
base region of the glycoprotein, and a wider panel of antibodies could assess specific changes in 
neutralization sensitivity at other sites. 
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The finding that both SEVI and SEVI-Ala enhance desiccation tolerance was unexpected. 
This finding supports a hypothesis that this stabilization effect occurs through a different 
mechanism than enhancement of infection or stability at physiological temperature. It may be that 
the large fibrillar structure is able to retain water, creating a local microenvironment in which the 
virion is protected from desiccation. The exact requirements for this effect remain unclear, as 
incubation with the amyloid α-synuclein had no effect on desiccation tolerance. To better define the 
mechanism, future studies could test desiccation tolerance in the presence of a panel of amyloid 
fiibrils to determine if this effect is specific to SEVI (and related peptides containing the same 
amyloidogenic domains, like SEVI-Ala). Specifically, the other seminal amyloids as well as their 
uncharged variants could be used to better understand this phenomenon. Lastly, several species 
of bacteria including E. coli have been identified to form extracellular amyloid fibrils using curli 
proteins10. Given that EVD is primarily a diarrheal disease, it would be highly clinically relevant if 
amyloid secretions by gut bacteria enhance either infection or environmental stability of EBOV. 
This could be tested by incubating rVSV-EboGP-mCherry with purified curli then testing for 
Figure 4.2. SEVI does not reduce neutralization sensitivity to anti-EboGP antibodies.19  
rVSV-EboGP-mCherry was pretreated or not with SEVI and incubated with different concentrations 
of anti-EboGP neutralizing antibody for 30 min at 37°C, then used to infect Vero cells. Infection was 
quantified by flow cytometry. n=1. 
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enhancement of infection and of stability enhancement. The finding that microbiota could play a 
role in EBOV transmission would be novel. 
 
Section 4.2.4 – Mechanisms of enhancement at the cellular and molecular level 
It is unclear how SEVI-mediated enhancement interacts with cellular attachment factors. 
Expression of attachment factors including DC-SIGN on the surface of cells increases their 
susceptibility to infection by EBOV and EboGP-expressing particles. It is unknown how 
enhancement of binding and especially internalization by SEVI is modulated by the presence of 
these attachment factors. It is possible that seminal amyloids and cellular attachment factors could 
synergize to result in an even greater increase in infection, or the presence of seminal amyloids 
could physically occlude binding sites on the virion to antagonize the effects of attachment factors. 
To assess these possibilities, HEK-293 cells that have a DC-SIGN gene under expression of a 
doxycycline-inducible promoter were infected in the presence or absence of physiologic levels of 
SEVI, in the presence or absence of doxycycline. No additional increases in rVSV-EboGP-mCherry 
infection were seen when SEVI was added to infection of cells expressing DC-SIGN by 
fluorescence microscopy, and quantification was not performed. However, for this experiment 
relatively high concentrations of SEVI (35 μg/mL) and doxycycline (2 μg/mL) were used, and each 
condition alone greatly increased infection. Each factor alone may enhance the entry process of 
rVSV-EboGP-mCherry to biologically maximal levels. To address this concern, future experiments 
are planned in which lower levels of SEVI (10 μg/mL) and doxycycline (0.2 μg/ml) are used in order 
to see any potential synergistic effects. These preliminary results do not support a model of 
antagonism between the fibrils and cellular attachment factors, at least as far as attachment factors 
that bind EboGP are concerned. PS-binding attachment factors may be more sensitive to occlusion 
of membrane phospholipids, and this can be tested in a similar fashion.  
 The enhancement of EBOV entry via increased macropinocytic uptake is an important new 
finding of this work, but the mechanism by which SEVI induces macropinocytosis is unknown. It is 
likely that the large, positively charged fibrils will engage multiple cell surface receptors in a 
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nonspecific manner to induce uptake. Macropinocytosis requires activation of Rho GTPases which 
regulate actin polymerization that forms membrane ruffles11,12. A number of kinases are also 
activated depending upon the upstream signal. Interestingly, while both antibody-dependent 
enhancement (ADE) of EBOV infection and antibody-independent infection require 
macropinocytosis as an entry mechanism, distinct intracellular signaling pathways are activated. 
While inhibition of the non-receptor tyrosine kinases Src and Syk have little impact on infection by 
rVSV-EboGP pseudotypes, antibody-enhanced infection is blocked in their presence13. These 
results indicate that internalization signals downstream of the Fc receptor are distinct from those 
normally activated during rVSV-EboGP pseudotype entry. To determine whether a similar disparity 
exists during SEVI-enhanced rVSV-EboGP-mCherry infection, HeLa cells were pretreated for 1 h 
with the Src inhibitor PP2 then infected with rVSV-EboGP-mCherry. Qualitative observation by 
fluorescence microscopy showed no differences in infection between treated and untreated 
samples in the presence or absence of SEVI (data not shown). These data do not support the 
hypothesis that SEVI-enhanced infection specifically requires a Src-dependent uptake mechanism 
and thus is dissimilar to Fc-mediated uptake of rVSV-EboGP. Further candidates, however, could 
be tested in the same way to determine if there is differential activation of intracellular signaling 
molecules during SEVI enhancement. 
 It is notable that sexual transmission of EBOV had not been previously described before 
the 2014 outbreak. While it is possible that EBOV sexual transmission is simply a rare event that 
has not occurred before this outbreak, it is also possible that mutations that arose during the 
outbreak contributed to sexual transmission. As previously described, the A82V mutation in EboGP 
became prominent during the outbreak14. This mutation results in an increase in particle infectivity 
but detracts from glycoprotein stability during incubations at physiological temperatures15. Notably, 
published sequences of sexually transmitted EBOV contain the V82 allele, though correlations are 
difficult to draw due to the small number of sequences available16. This work describes a novel 
function of SEVI to enhance viral stability under those same conditions. It is possible that SEVI 
increases stability of the virion to mitigate this decrease in stability. This would result in viral stability 
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being perhaps unchanged while the particle is more infective during the transmission event. To test 
this hypothesis, the rVSV-EboGP-mCherry vector is being mutagenized to replace the ancestral 
A82 allele with V82. After rescue of infectious virus by previously described mechanisms, the A82 
and V82 viruses will be compared in their relative stabilities in the presence and absence of SEVI. 
If the stability of the V82 virus increases disproportionately in the presence of SEVI, this would 
provide support to a hypothesis that this interaction may be important for sexual transmission. 
 
Section 4.2.5 – Implications for antiviral development 
The identification of a pro-viral component of semen presents an exciting opportunity for 
the development of antivirals that can target the interaction. In this manner, both the molecular 
enhancement mechanism as well as the enhancement of environmental stability could be 
ameliorated. There has been significant interest in developing compounds that disassemble 
amyloid fibrils, both in the context of SEVI and otherwise. Recently, it has been demonstrated that 
CLR01, a molecule designed to mask the positive charge of amyloids but that was subsequently 
found to disrupt viral membranes, has activity against EBOV pseudoviruses17,18. It will be interesting 
to see the extent to which existing anti-amyloid compounds affect whether these compounds have 
effects on the environmental stabilization properties of SEVI in addition to its infection-
enhancement activity. In particular, the finding that SEVI-Ala enhances desiccation tolerance may 
require development of broader-acting anti-amyloid agents. While SEVI-Ala is not naturally 
occurring and thus not per se a concern, its activity raises the possibility that other amyloids or 
aggregates may demonstrate similar actions that should also be targeted for maximal impact. 
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Section 4.3 – Concluding remarks 
In conclusion, this work identifies for the first time that EBOV infection can be enhanced by 
amyloid fibrils present in human semen. These fibrils act to enhance infection at a molecular level 
by increasing particle binding and internalization by increasing macropinocytosis in target cells. 
Further, a novel function of SEVI to enhance stability in the environment is described, suggesting 
a potential role for these fibrils in transmission dynamics. This represents the first pro-viral host 
factor identified in the context of EBOV sexual transmission and may represent a viable target for 
therapeutic options moving forward. 
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Section 4.4 – Materials and methods for preliminary work 
This section provides materials and methods information for experiments not described in Section 
3.4. 
 
ZIKV infection assays. A549 cells were plated at 1.5e4 cells/well one day prior to infection. ZIKV 
MR766 or ZIKV Mex 2-81 (Susan Weiss, U. Pennsylvania) were diluted in DMEM-10 in the 
presence or absence of SEVI and used to infect cells at MOI 1 as calculated by plaque assay on 
Vero cells. After 1 h, infection medium was replaced with fresh DMEM-10. After 16-20 h, cells were 
trypsinized and fixed in 2% paraformaldehyde for >20 min. Cells were permeablized in 0.1% 
saponin in FACS buffer (1% BSA in PBS) for 25 minutes, then incubated in FACS buffer with 
saponin with the “pan-flavivirus” 4G2 antibody for 1 h, then anti-mouse AF647-conjugated 
secondary antibody for 1 h. Infection was quantified by flow cytometry. 
 
Protease treatment. rVSV-EboGP-mCherry was diluted in serum-free DMEM. TPCK trypsin or 
proteinase K were added to final concentrations of 50 μg/mL or 20 μg/mL, respectively. The virus 
was then incubated for 30 minutes at 37°C. Digestion was halted with DMEM-10 containing 
soybean trypsin inhibitor or DMEM-10 alone. Afterward, virus was titered by TCID50 on Vero cells. 
 
Antibody neutralization. rVSV-EboGP-mCherry was incubated with SEVI, then added to serial 
dilutions of anti-EboGP antibodies (gift from Erica Ollmann-Saphire, Scripps Research Institute) for 
1 h at 37°C. Mixtures were then used to infect Vero cells for 1 h. Afterward, infection medium was 
replaced with fresh DMEM-10 and the infection was permitted to proceed for 12 h total. Cells were 
trypsinized and analyzed by flow cytometry for percent infection, then relative percents infection 
were used to calculate IC50 values (GraphPad Prism). 
 
DC-SIGN cells. 293 T-Rex DC-SIGN cells were maintained in DMEM-10 without doxycycline. To 
upregulate DC-SIGN, the cells were treated for 24 h prior to infection with 2 μg/mL doxycycline. 
 
Inhibitor treatments. HeLa cells were treated with the Src inhibitor PP2 (10 μM) for 1 h prior to and 
1 h during infection with rVSV-EboGP-mCherry in the presence or absence of SEVI.  
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APPENDIX – IDENTIFICATION OF HOST FACTORS THAT RESTRICT ZIKA VIRUS 
INFECTION 
Stephen M. Bart1, Kangjian Zhang2, Angelíca Ortiz2, Serge Y. Fuchs2, Paul Bates1 
1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania 
2Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania 
 
In addition to identification of seminal amyloids as a host factor that enhanced EBOV 
infection, I have conducted work to identify factors that restrict viral infection. Specifically, I have 
developed a system in which factors that promote cell survival after viral challenge can be enriched 
from a genome-wide pool. This ongoing work seeks to identify factors that restrict Zika virus 
replication. K. Zhang and A. Ortiz in the Fuchs lab assisted in the generation of IFNAR1 KO cells 
using reagents developed and produced by me. I conceived and conducted the remainder of the 
experiments and wrote this appendix under the supervision of Paul Bates. 
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Section 1.1 – Introduction 
Zika virus (ZIKV) was discovered in Uganda in 1947 and identified as a member of the 
Flaviviridae family. The virus, which was traditionally restricted to Africa and Asia, emerged in 
several Pacific islands before spreading to the Americas during the 2015-2016 Zika epidemic. The 
epidemic was marked by a sharp uptick in the number of cases of microcephaly, other birth defects, 
and Guillain-Barré syndrome, prompting the World Health Organization to declare a Public Health 
Emergency of International Concern1–5.  
The interactions of ZIKV with host cells are poorly characterized. Several loss-of-function 
screens have been performed to identify factors required for ZIKV replication6–8. Several factors 
that inhibit ZIKV replication have also been described; these mainly focus upon the interferon 
response. ZIKV replication is antagonized by the action of types I and III interferon9,10, which induce 
a signaling cascade leading to the expression of numerous interferon-stimulated genes (ISGs). 
These genes, among other functions, encode factors with antiviral activity to inhibit viral replication. 
Screens employing cDNAs of various ISGs have been used to identify which factors out of the 
hundreds of ISGs act upon specific viruses to limit their replication. The breadth of factors that 
affect ZIKV replication is unknown, but IFITM1, IFITM3 and viperin have each been described to 
inhibit ZIKV replication11–13. It is further probable that there are cellular factors that are not 
necessarily interferon-stimulated that also have antiviral activity. The zinc metallopeptidase 
ZMPSTE24 has recently been described to have anti-ZIKV activity in a mechanism involving 
IFITMs14. A systematic exploration of factors involved in ZIKV restriction, whether interferon-
dependent or not, has not been conducted. 
Recently, CRISPR/Cas9 technology has been adapted to allow for targeting gene 
activation. One system, synergistic activation mediators (SAM), uses transcriptional coactivators 
derived from NF-κB (p65), HSF1, and VP64 along with a modified guide RNA in order to target an 
activating Cas9 to a specific locus and upregulate gene expression. When a pool of cells is 
transduced with a library of guide RNAs then challenged with some selective pressure, factors that 
promote cellular tolerance to that stress are enriched. This library targets 23,430 genes in triplicate 
 
86 
for a total of 70,290 guide RNAs. These factors can be identified by comparing the abundance of 
each guide RNA in the selected population against unselected cells15. This technology has 
identified that sialic acid-modifying enzymes have anti-influenza activity by reducing receptor 
binding16. 
This report describes the generation and characterization of cells to perform a SAM screen 
to identify factors with antiviral activity against ZIKV. 
Section 1.2 – Materials and Methods 
Cells and viruses. A549 cells (ATCC) were maintained in F12K media supplemented with 
10% FBS (Sigma), 293T (ATCC) and Vero CCL81 cells (gift from Susan Weiss, U. Pennsylvania) 
were maintained in DMEM with 4.5 g/L glucose and no sodium pyruvate supplemented with 10% 
FBS (Sigma). ZIKV MR766 (gift from Susan Weiss, U. Pennsylvania) and ZIKV Mex 2-81 (gift from 
Scott Hensley, U. Pennsylvania) were propogated in Vero cells. Newcastle disease virus-GFP was 
a gift from Susan Weiss, U. Pennsylvania. 
Plasmids. plentiCRISPR (AddGene) was modified to contain a loxP site within the 5’ long 
terminal repeat (lentiCRISPRloxP) by restriction enzyme cloning and insertion of a gBlock (IDT). 
Components of the SAM system (lentiviral plasmids encoding dCas9-VP64, MS2-p65-HSF1, guide 
RNA library) were acquired from AddGene and the SAM library was propagated according to 
AddGene instructions. The gRNA2.0 plasmid was also modified to express GFP in place of the 
drug resistance marker. 
Lentivirus production and transduction. Lentiviral pseudotypes were generated by 
transfecting 15 μg genome plasmid, 10.5 μg pSPAX2, and 3.75 μg VSV G with polyethylenimine 
into a 15 cm plate of 293T cells. Supernatants were harvested 24-48 h post-transfection, clarified 
by centrifugation, and frozen at -80°C. 
qPCR. DNA was extracted from half of a 24-well plate well according to manufacturer’s 
protocols (Qiagen Blood and Tissue Kit). 5 μL of DNA was used per reaction along with 2 μL of 5 
μM combined F and R plasmids (Cas9, puromycin, or GAPDH), 3 μL water, and 10 μL SYBER 2X 
master mix. After qPCR, data were analyzed by ddCt method. 
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Flow cytometry. Cells were trypsinized, fixed in 2% PFA, then permeablized for >20 
minutes with saponin. Cells were incubated with 4G2 antibody (gift from Sara Cherry, U. 
Pennsylvania) for 1 h in FACS buffer (1% BSA in PBS) with saponin (4G2 1:4000) then incubated 
with AF647-anti-mouse secondary antibody (1:5000) for 1 h. After resuspending cells in FACS 
buffer without saponin, cells were ran on LSRII and data analyzed with FlowJo. 
Section 1.3 – Results 
A549 cells were selected for the screen because of the cells’ intact intrinsic immune system 
as well as the ability of ZIKV to induce cytopathic effect (data not shown). To reduce interferon 
signaling, which may result in nonspecific survival of cells and increase screen background, a 
modified lentiCRISPR construct was first used to knock out the IFNAR1 gene, a component of the 
type I interferon receptor. To avoid downstream “crosstalk” between the nucleolytic Cas9 used for 
knockout and the catalytically inactive Cas9 used in SAM, the lentiCRISPR vector was modified 
such that the lentiviral genome contains loxP sites within the LTRs (Fig A.1A). After treatment of 
cells with Cre recombinase, the genome (including Cas9) is excised, leaving only a single LTR 
element integrated into the genome. A549 cells were transduced with lentiCRISPRloxP containing 
a guide against IFNAR1, then single cell cloned. Clones were screened for knockout by treatment 
with interferon-α and γ; a putative IFNAR1 KO clone (1-4) exhibited phosphorylation of STAT1 in 
response to IFN- γ but not α (Fig A.1B). Inactivation of IFNAR1 was further confirmed by cell-
surface staining for IFNAR and analyzing cells by flow cytometry (data not shown) and genomic 
sequencing of the IFNAR1 gene (Fig A.1C). 
IFNAR1 KO clones also exhibited a functional inability to respond to exogenous IFN-α. 
Cells were pretreated for 24 h with 500 U/mL IFN-α then infected with Newcastle disease virus that 
expresses GFP (NDV-GFP). This virus is exquisitely sensitive to IFN and is used as a biosensor 
for IFN activity17. As opposed to wild type cells that become resistant to NDV-GFP infection after 
IFN treatment, knockout cells show no difference in infectivity (Fig A.1D). Lastly, knockout cells 
were infected with ZIKV MR766 at a multiplicity of infection (MOI) of 0.1 for 3 days. At that point, 
the supernatants were harvested, cleared of cell debris by centrifugation, and UV-treated to 
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inactivate virus. This supernatant was applied to WT or KO cells for 24 h prior to infection with ZIKV 
MR766. While the supernatant led to a decrease in infection in WT cells, no difference was seen 
in infection among treated or untreated KO cells (Fig A.1E). This indicates that the cytokines 
produced during ZIKV infection of IFNAR KO A549 cells do not induce an antiviral state in other 
IFNAR KO cells, a key requirement for screening. 
IFNAR KO cells were then transduced with lentiviral vectors containing the dCas9-VP64 
and MS2-p65-HSF1 expression vectors as well as Ad-Cre to remove the integrated provirus 
genome containing Cas9. After selection with blasticidin and hygromycin, cells were single cell 
cloned. Individual clones were then harvested for genomic DNA that was subsequently subjected 
to qPCR to identify clones negative for the integrated provirus, as marked by the puromycin 
resistance gene. While the parent IFNAR KO cells exhibited high Cas9 and puromycin signal 
compared to the GAPDH control, several clones showed ablation of the puromycin signal (Fig 
A.2A). These puromycin-negative clones were then screened for the clone that had the highest 
activity for upregulation of target genes. Cells were transduced with a lentiviral vector containing a 
sgRNA for CD4 as well as a GFP marker and analyzed by flow cytometry. CD4 was chosen 
because of the abundance of reagents to detect the molecule as well as its lack of expression on 
A549 cells. Cells exhibited a range of expression profiles, including no upregulation, upregulation 
in a subset of cells, or full upregulation (Fig A.2B). Two clones exhibited full upregulation, and these 
cells were independently transduced with three different guides targeting IRF1, an antiviral gene 
with wide activity, again with a GFP marker. ZIKV infection (assessed by immunostaining for ZIKV 
E) was compared among GFP- (untransduced) cells as well as GFP+ (IRF1 guide transduced 
cells). Clone 1.9 was found to have lower relative levels of infection among GFP+ cells in 2/3 guides 
compared to clone 1.6, and thus was selected to proceed for screening (Fig A.2C). 
Cells of the Clone 1.9 lineage were renamed SAM cells, were expanded, and transduced 
with the guide RNA library containing 70,290 guides at an MOI of 0.2. Library was titered by 
counting number of cells following treatment with Zeocin following several rounds of replating at 
low densities. Cells were transduced at a level designed to give at least 500 transduced cells per 
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each guide. After 7 days to permit expansion and gene upregulation, cells were infected with ZIKV 
at MOI 1 or passaged in parallel without infection. After 4 days, the cells were washed vigorously 
and harvested for DNA to be used in sequencing (Fig A.3). 
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rn
 b
lo
t u
s
e
d
 to
 s
c
re
e
n
 
c
lo
n
e
s
 a
fte
r p
u
ro
m
y
c
in
 s
e
le
c
tio
n
. C
. S
e
q
u
e
n
c
in
g
 fro
m
 th
e
 IF
N
A
R
1
 lo
c
u
s
 in
 p
a
re
n
ta
l c
e
lls
 o
r c
lo
n
e
d
 C
R
IS
P
R
 c
e
lls
. 
D
. R
e
la
tiv
e
 N
D
V
-G
F
P
 in
fe
c
tio
n
 in
 th
e
 p
re
s
e
n
c
e
 o
r a
b
s
e
n
c
e
 o
f in
te
rfe
ro
n
-α
 p
re
tre
a
tm
e
n
t. n
=
3
; m
e
a
n
±
S
E
M
, *p
<
0
.0
5
 
b
y
 re
p
e
a
te
d
 m
e
a
s
u
re
s
 A
N
O
V
A
 o
f lo
g
-tra
n
s
fo
rm
e
d
 p
e
rc
e
n
ts
 in
fe
c
tio
n
. E
. R
e
la
tiv
e
 Z
IK
V
 in
fe
c
tio
n
 in
 th
e
 p
re
s
e
n
c
e
 o
r 
a
b
s
e
n
c
e
 o
f c
o
n
d
itio
n
e
d
, U
V
-in
a
c
tiv
a
te
d
 s
u
p
e
rn
a
ta
n
t. n
=
2
; m
e
a
n
±
S
D
. 
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F
ig
u
re
 A
.2
. G
e
n
e
ra
tio
n
 o
f S
A
M
 c
e
lls
 fo
r s
c
re
e
n
in
g
. 2
1
 
A
. q
P
C
R
 s
c
re
e
n
in
g
 o
f c
lo
n
e
s
 a
fte
r tra
n
s
d
u
c
tio
n
 w
ith
 S
A
M
 c
o
m
p
o
n
e
n
ts
 a
n
d
 A
d
-C
re
. P
u
ro
 a
n
d
 C
a
s
9
 s
ig
n
a
l is
 re
la
tiv
e
 to
 g
e
n
o
m
ic
 
G
A
P
D
H
 a
n
d
 n
o
rm
a
liz
e
d
 to
 th
e
 c
lo
n
a
l IF
N
A
R
 K
O
 p
a
re
n
ta
l c
e
lls
. L
a
c
k
 o
f p
u
ro
m
y
c
in
 s
ig
n
a
l in
d
ic
a
te
s
 s
u
c
c
e
s
s
fu
l e
x
c
is
io
n
 o
f 
le
n
tiC
R
IS
P
R
lo
x
P
 
c
a
s
s
e
tte
; 
C
a
s
9
 
s
ig
n
a
l 
c
a
n
 
b
e
 
fro
m
 
e
ith
e
r 
le
n
tiC
R
IS
P
R
lo
x
P
 
C
a
s
9
 
g
e
n
e
 
o
r 
S
A
M
 
d
C
a
s
9
-V
P
6
4
 
g
e
n
e
. 
B
. 
R
e
p
re
s
e
n
ta
tiv
e
 flo
w
 p
lo
ts
 o
f S
A
M
 c
lo
n
e
s
 a
fte
r tra
n
s
d
u
c
tio
n
 w
ith
 le
n
tis
g
R
N
A
_
C
D
4
_
G
F
P
. R
e
d
 p
e
a
k
s
 a
re
 G
F
P
- c
e
lls
 th
a
t d
o
 n
o
t 
h
a
v
e
 th
e
 C
D
4
 g
u
id
e
. B
lu
e
 p
e
a
k
s
 in
d
ic
a
te
 c
e
lls
 th
a
t e
x
p
re
s
s
 G
F
P
 a
n
d
 th
u
s
 a
re
 C
D
4
 g
u
id
e
 tra
n
s
d
u
c
e
d
; n
=
1
. C
. R
e
la
tiv
e
 Z
IK
V
 
in
fe
c
tio
n
 (q
u
a
n
tifie
d
 b
y
 flo
w
 c
y
to
m
e
try
) o
f S
A
M
 c
lo
n
e
s
 tra
n
s
d
u
c
e
d
 w
ith
 IR
F
1
 g
u
id
e
s
; n
=
1
. D
.  R
e
la
tiv
e
 e
n
ric
h
m
e
n
t fo
r le
n
tis
g
R
N
A
 
s
e
q
u
e
n
c
e
 (q
u
a
n
tifie
d
 b
y
 q
P
C
R
) a
fte
r s
e
le
c
tio
n
 w
ith
 Z
IK
V
 M
R
7
6
6
 fo
r 3
 d
a
y
s
.  
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ig
u
re
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. S
c
h
e
m
a
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c
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e
n
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g
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5
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9
 S
A
M
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